TW200938221A - Protein formulations and methods of making same - Google Patents

Protein formulations and methods of making same Download PDF

Info

Publication number: TW200938221A
Authority: TW; Taiwan
Prior art keywords: formulation; protein; concentration; solution; antibody
Prior art date: 2007-11-30

Application number

TW097146498A

Other languages

English (en)

Chinese (zh)

Inventor

Wolfgang Fraunhofer

Annika Bartl

Hans-Juergen Krause

Markus Tschoepe

Katharina Kaleta

Original Assignee

Abbott Lab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-11-30

Filing date

2008-11-28

Publication date

2009-09-16

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40718465&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW200938221(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-11-28 Application filed by Abbott Lab filed Critical Abbott Lab

2009-09-16 Publication of TW200938221A publication Critical patent/TW200938221A/zh

Links

108090000623 proteins and genes Proteins 0.000 title claims abstract description 497
102000004169 proteins and genes Human genes 0.000 title claims abstract description 490
239000000203 mixture Substances 0.000 title claims abstract description 358
238000009472 formulation Methods 0.000 title claims abstract description 310
238000000034 method Methods 0.000 title claims abstract description 182
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 341
229910001868 water Inorganic materials 0.000 claims abstract description 190
239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 134
239000013011 aqueous formulation Substances 0.000 claims abstract description 97
239000000243 solution Substances 0.000 claims description 259
239000003814 drug Substances 0.000 claims description 100
238000011026 diafiltration Methods 0.000 claims description 69
239000000427 antigen Substances 0.000 claims description 66
239000012460 protein solution Substances 0.000 claims description 66
108091007433 antigens Proteins 0.000 claims description 65
102000036639 antigens Human genes 0.000 claims description 65
230000035699 permeability Effects 0.000 claims description 63
239000012634 fragment Substances 0.000 claims description 61
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 32
229930195725 Mannitol Natural products 0.000 claims description 32
239000000594 mannitol Substances 0.000 claims description 32
235000010355 mannitol Nutrition 0.000 claims description 32
230000001225 therapeutic effect Effects 0.000 claims description 31
239000007924 injection Substances 0.000 claims description 30
238000002347 injection Methods 0.000 claims description 30
238000004519 manufacturing process Methods 0.000 claims description 29
239000003795 chemical substances by application Substances 0.000 claims description 28
239000007788 liquid Substances 0.000 claims description 25
108010050904 Interferons Proteins 0.000 claims description 23
102000014150 Interferons Human genes 0.000 claims description 23
229940079322 interferon Drugs 0.000 claims description 22
-1 mannitol or sterol Chemical class 0.000 claims description 21
230000002378 acidificating effect Effects 0.000 claims description 20
210000004027 cell Anatomy 0.000 claims description 20
108010081589 Becaplermin Proteins 0.000 claims description 19
239000004094 surface-active agent Substances 0.000 claims description 19
229960002964 adalimumab Drugs 0.000 claims description 18
239000008194 pharmaceutical composition Substances 0.000 claims description 16
239000012141 concentrate Substances 0.000 claims description 15
239000000047 product Substances 0.000 claims description 15
229960005267 tositumomab Drugs 0.000 claims description 15
102100040990 Platelet-derived growth factor subunit B Human genes 0.000 claims description 11
HYNPZTKLUNHGPM-KKERQHFVSA-N becaplermin Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc2cnc[nH]2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]5CCCN5C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H]6CCCN6C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]7CCCN7C(=O)[C@H](Cc8c[nH]c9c8cccc9)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCSC)NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)N HYNPZTKLUNHGPM-KKERQHFVSA-N 0.000 claims description 11
229960004787 becaplermin Drugs 0.000 claims description 11
239000007853 buffer solution Substances 0.000 claims description 11
238000005119 centrifugation Methods 0.000 claims description 11
235000013601 eggs Nutrition 0.000 claims description 11
RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 claims description 10
MJZJYWCQPMNPRM-UHFFFAOYSA-N 6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,6-dihydro-1,3,5-triazine-2,4-diamine Chemical compound CC1(C)N=C(N)N=C(N)N1OCCCOC1=CC(Cl)=C(Cl)C=C1Cl MJZJYWCQPMNPRM-UHFFFAOYSA-N 0.000 claims description 10
230000004071 biological effect Effects 0.000 claims description 10
229960001001 ibritumomab tiuxetan Drugs 0.000 claims description 10
238000000338 in vitro Methods 0.000 claims description 10
229960001972 panitumumab Drugs 0.000 claims description 10
229960004641 rituximab Drugs 0.000 claims description 10
241000894007 species Species 0.000 claims description 10
229960003824 ustekinumab Drugs 0.000 claims description 10
229960003297 gemtuzumab ozogamicin Drugs 0.000 claims description 9
108010019673 Darbepoetin alfa Proteins 0.000 claims description 8
108010074604 Epoetin Alfa Proteins 0.000 claims description 8
108010008165 Etanercept Proteins 0.000 claims description 8
101001018026 Homo sapiens Lysosomal alpha-glucosidase Proteins 0.000 claims description 8
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 8
229930006000 Sucrose Natural products 0.000 claims description 8
108090000373 Tissue Plasminogen Activator Proteins 0.000 claims description 8
102000003978 Tissue Plasminogen Activator Human genes 0.000 claims description 8
108010017271 denileukin diftitox Proteins 0.000 claims description 8
108010067396 dornase alfa Proteins 0.000 claims description 8
108010089296 galsulfase Proteins 0.000 claims description 8
102000045921 human GAA Human genes 0.000 claims description 8
108010072166 idursulfase Proteins 0.000 claims description 8
238000001727 in vivo Methods 0.000 claims description 8
239000004615 ingredient Substances 0.000 claims description 8
239000002953 phosphate buffered saline Substances 0.000 claims description 8
229920005862 polyol Polymers 0.000 claims description 8
150000003077 polyols Chemical class 0.000 claims description 8
229940107568 pulmozyme Drugs 0.000 claims description 8
108010084837 rasburicase Proteins 0.000 claims description 8
229940116157 regranex Drugs 0.000 claims description 8
108010051412 reteplase Proteins 0.000 claims description 8
108010017584 romiplostim Proteins 0.000 claims description 8
239000005720 sucrose Substances 0.000 claims description 8
108010029961 Filgrastim Proteins 0.000 claims description 7
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 7
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 7
108010078049 Interferon alpha-2 Proteins 0.000 claims description 7
102000051628 Interleukin-1 receptor antagonist Human genes 0.000 claims description 7
108700021006 Interleukin-1 receptor antagonist Proteins 0.000 claims description 7
229930182558 Sterol Natural products 0.000 claims description 7
239000007864 aqueous solution Substances 0.000 claims description 7
229940048921 humira Drugs 0.000 claims description 7
229960000598 infliximab Drugs 0.000 claims description 7
108010010648 interferon alfacon-1 Proteins 0.000 claims description 7
108010046821 oprelvekin Proteins 0.000 claims description 7
108010044644 pegfilgrastim Proteins 0.000 claims description 7
239000012466 permeate Substances 0.000 claims description 7
238000000746 purification Methods 0.000 claims description 7
108010074523 rimabotulinumtoxinB Proteins 0.000 claims description 7
150000003432 sterols Chemical class 0.000 claims description 7
235000003702 sterols Nutrition 0.000 claims description 7
241000196324 Embryophyta Species 0.000 claims description 6
108010005716 Interferon beta-1a Proteins 0.000 claims description 6
229960001743 golimumab Drugs 0.000 claims description 6
229940038850 rebif Drugs 0.000 claims description 6
239000003381 stabilizer Substances 0.000 claims description 6
238000007920 subcutaneous administration Methods 0.000 claims description 6
229940099073 xolair Drugs 0.000 claims description 6
HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 5
101710117542 Botulinum neurotoxin type A Proteins 0.000 claims description 5
QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 claims description 5
HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 5
XYVNHPYNSPGYLI-UUOKFMHZSA-N [(2r,3s,4r,5r)-5-(2-amino-6-oxo-3h-purin-9-yl)-4-hydroxy-2-(phosphonooxymethyl)oxolan-3-yl] dihydrogen phosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H]1O XYVNHPYNSPGYLI-UUOKFMHZSA-N 0.000 claims description 5
229960000446 abciximab Drugs 0.000 claims description 5
229960002459 alefacept Drugs 0.000 claims description 5
229960000548 alemtuzumab Drugs 0.000 claims description 5
HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 5
229950005725 arcitumomab Drugs 0.000 claims description 5
229940120638 avastin Drugs 0.000 claims description 5
229960004669 basiliximab Drugs 0.000 claims description 5
229960000397 bevacizumab Drugs 0.000 claims description 5
229940089093 botox Drugs 0.000 claims description 5
229940112129 campath Drugs 0.000 claims description 5
229940034605 capromab pendetide Drugs 0.000 claims description 5
229960003115 certolizumab pegol Drugs 0.000 claims description 5
229960005395 cetuximab Drugs 0.000 claims description 5
229940090100 cimzia Drugs 0.000 claims description 5
239000002577 cryoprotective agent Substances 0.000 claims description 5
229960002806 daclizumab Drugs 0.000 claims description 5
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims description 5
229960002224 eculizumab Drugs 0.000 claims description 5
229940082789 erbitux Drugs 0.000 claims description 5
229940022353 herceptin Drugs 0.000 claims description 5
229950007354 imciromab Drugs 0.000 claims description 5
238000011068 loading method Methods 0.000 claims description 5
229960003816 muromonab-cd3 Drugs 0.000 claims description 5
239000002736 nonionic surfactant Substances 0.000 claims description 5
229960000470 omalizumab Drugs 0.000 claims description 5
229940029358 orthoclone okt3 Drugs 0.000 claims description 5
229960000402 palivizumab Drugs 0.000 claims description 5
229940067082 pentetate Drugs 0.000 claims description 5
229940116176 remicade Drugs 0.000 claims description 5
229940107685 reopro Drugs 0.000 claims description 5
229940115586 simulect Drugs 0.000 claims description 5
229940055944 soliris Drugs 0.000 claims description 5
239000007921 spray Substances 0.000 claims description 5
150000005846 sugar alcohols Chemical class 0.000 claims description 5
229940036185 synagis Drugs 0.000 claims description 5
229960000575 trastuzumab Drugs 0.000 claims description 5
OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 4
108010024976 Asparaginase Proteins 0.000 claims description 4
102000015790 Asparaginase Human genes 0.000 claims description 4
108090000385 Fibroblast growth factor 7 Proteins 0.000 claims description 4
102000003972 Fibroblast growth factor 7 Human genes 0.000 claims description 4
102100039619 Granulocyte colony-stimulating factor Human genes 0.000 claims description 4
101001081555 Homo sapiens Plasma protease C1 inhibitor Proteins 0.000 claims description 4
102100029199 Iduronate 2-sulfatase Human genes 0.000 claims description 4
108010005714 Interferon beta-1b Proteins 0.000 claims description 4
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 4
GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 4
108091000080 Phosphotransferase Proteins 0.000 claims description 4
108010039185 Tenecteplase Proteins 0.000 claims description 4
GYDJEQRTZSCIOI-UHFFFAOYSA-N Tranexamic acid Chemical compound NCC1CCC(C(O)=O)CC1 GYDJEQRTZSCIOI-UHFFFAOYSA-N 0.000 claims description 4
229960003697 abatacept Drugs 0.000 claims description 4
229940099550 actimmune Drugs 0.000 claims description 4
229940099983 activase Drugs 0.000 claims description 4
108010056760 agalsidase beta Proteins 0.000 claims description 4
108700025316 aldesleukin Proteins 0.000 claims description 4
229960005310 aldesleukin Drugs 0.000 claims description 4
229940022705 aldurazyme Drugs 0.000 claims description 4
229960004593 alglucosidase alfa Drugs 0.000 claims description 4
229960003318 alteplase Drugs 0.000 claims description 4
239000003708 ampul Substances 0.000 claims description 4
239000003963 antioxidant agent Substances 0.000 claims description 4
229940115115 aranesp Drugs 0.000 claims description 4
229940094361 arcalyst Drugs 0.000 claims description 4
229940009098 aspartate Drugs 0.000 claims description 4
229940021459 betaseron Drugs 0.000 claims description 4
229940088949 cinryze Drugs 0.000 claims description 4
108010084052 continuous erythropoietin receptor activator Proteins 0.000 claims description 4
229960005029 darbepoetin alfa Drugs 0.000 claims description 4
229960002923 denileukin diftitox Drugs 0.000 claims description 4
229940056176 drotrecogin alfa Drugs 0.000 claims description 4
108010008250 drotrecogin alfa activated Proteins 0.000 claims description 4
229940012882 elaprase Drugs 0.000 claims description 4
229940053603 elitek Drugs 0.000 claims description 4
229940073038 elspar Drugs 0.000 claims description 4
229940073621 enbrel Drugs 0.000 claims description 4
229960003388 epoetin alfa Drugs 0.000 claims description 4
229940089118 epogen Drugs 0.000 claims description 4
229960000403 etanercept Drugs 0.000 claims description 4
229940014516 fabrazyme Drugs 0.000 claims description 4
229960005390 galsulfase Drugs 0.000 claims description 4
235000012907 honey Nutrition 0.000 claims description 4
102000044507 human SERPING1 Human genes 0.000 claims description 4
229960002396 idursulfase Drugs 0.000 claims description 4
239000007943 implant Substances 0.000 claims description 4
229940090438 infergen Drugs 0.000 claims description 4
108010042414 interferon gamma-1b Proteins 0.000 claims description 4
238000007912 intraperitoneal administration Methods 0.000 claims description 4
229940065638 intron a Drugs 0.000 claims description 4
229940065223 kepivance Drugs 0.000 claims description 4
229940054136 kineret Drugs 0.000 claims description 4
229960002486 laronidase Drugs 0.000 claims description 4
229940029238 mircera Drugs 0.000 claims description 4
239000003607 modifier Substances 0.000 claims description 4
229940112646 myobloc Drugs 0.000 claims description 4
229940103023 myozyme Drugs 0.000 claims description 4
229940068704 naglazyme Drugs 0.000 claims description 4
229940071846 neulasta Drugs 0.000 claims description 4
229940082926 neumega Drugs 0.000 claims description 4
229940029345 neupogen Drugs 0.000 claims description 4
229940100027 ontak Drugs 0.000 claims description 4
229960002404 palifermin Drugs 0.000 claims description 4
229940002988 pegasys Drugs 0.000 claims description 4
108010092853 peginterferon alfa-2a Proteins 0.000 claims description 4
102000020233 phosphotransferase Human genes 0.000 claims description 4
229960000424 rasburicase Drugs 0.000 claims description 4
229940116243 retavase Drugs 0.000 claims description 4
229960002917 reteplase Drugs 0.000 claims description 4
108010046141 rilonacept Proteins 0.000 claims description 4
229960001886 rilonacept Drugs 0.000 claims description 4
229960004262 romiplostim Drugs 0.000 claims description 4
WUWDLXZGHZSWQZ-WQLSENKSSA-N semaxanib Chemical compound N1C(C)=CC(C)=C1\C=C/1C2=CC=CC=C2NC\1=O WUWDLXZGHZSWQZ-WQLSENKSSA-N 0.000 claims description 4
229940113038 tnkase Drugs 0.000 claims description 4
HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 claims description 3
102100039350 Interferon alpha-7 Human genes 0.000 claims description 3
102100030694 Interleukin-11 Human genes 0.000 claims description 3
201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 3
208000007541 Preleukemia Diseases 0.000 claims description 3
108010057266 Type A Botulinum Toxins Proteins 0.000 claims description 3
229960004238 anakinra Drugs 0.000 claims description 3
230000003078 antioxidant effect Effects 0.000 claims description 3
229960001776 edrecolomab Drugs 0.000 claims description 3
229960004177 filgrastim Drugs 0.000 claims description 3
229960003358 interferon alfacon-1 Drugs 0.000 claims description 3
238000007918 intramuscular administration Methods 0.000 claims description 3
238000001990 intravenous administration Methods 0.000 claims description 3
210000004962 mammalian cell Anatomy 0.000 claims description 3
229960001840 oprelvekin Drugs 0.000 claims description 3
229940035567 orencia Drugs 0.000 claims description 3
HQQSBEDKMRHYME-UHFFFAOYSA-N pefloxacin mesylate Chemical compound [H+].CS([O-])(=O)=O.C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCN(C)CC1 HQQSBEDKMRHYME-UHFFFAOYSA-N 0.000 claims description 3
229960001373 pegfilgrastim Drugs 0.000 claims description 3
230000003204 osmotic effect Effects 0.000 claims description 2
210000002307 prostate Anatomy 0.000 claims 3
MCNQUWLLXZZZAC-UHFFFAOYSA-N 4-cyano-1-(2,4-dichlorophenyl)-5-(4-methoxyphenyl)-n-piperidin-1-ylpyrazole-3-carboxamide Chemical compound C1=CC(OC)=CC=C1C1=C(C#N)C(C(=O)NN2CCCCC2)=NN1C1=CC=C(Cl)C=C1Cl MCNQUWLLXZZZAC-UHFFFAOYSA-N 0.000 claims 1
229940122601 Esterase inhibitor Drugs 0.000 claims 1
240000007594 Oryza sativa Species 0.000 claims 1
235000007164 Oryza sativa Nutrition 0.000 claims 1
GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 claims 1
239000004067 bulking agent Substances 0.000 claims 1
239000007933 dermal patch Substances 0.000 claims 1
239000002329 esterase inhibitor Substances 0.000 claims 1
239000003112 inhibitor Substances 0.000 claims 1
238000002386 leaching Methods 0.000 claims 1
235000009566 rice Nutrition 0.000 claims 1
239000003053 toxin Substances 0.000 claims 1
231100000765 toxin Toxicity 0.000 claims 1
235000018102 proteins Nutrition 0.000 description 424
101100026709 Mus musculus Nprl3 gene Proteins 0.000 description 140
239000008215 water for injection Substances 0.000 description 135
239000000523 sample Substances 0.000 description 100
229940079593 drug Drugs 0.000 description 93
238000004458 analytical method Methods 0.000 description 70
238000001542 size-exclusion chromatography Methods 0.000 description 57
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 54
238000011282 treatment Methods 0.000 description 50
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 41
238000002296 dynamic light scattering Methods 0.000 description 41
238000004255 ion exchange chromatography Methods 0.000 description 40
239000000872 buffer Substances 0.000 description 39
238000009295 crossflow filtration Methods 0.000 description 35
239000000178 monomer Substances 0.000 description 29
239000002609 medium Substances 0.000 description 27
239000011780 sodium chloride Substances 0.000 description 27
238000000889 atomisation Methods 0.000 description 25
238000003860 storage Methods 0.000 description 24
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 22
239000012615 aggregate Substances 0.000 description 22
238000005325 percolation Methods 0.000 description 22
206010057190 Respiratory tract infections Diseases 0.000 description 21
238000005516 engineering process Methods 0.000 description 21
238000002474 experimental method Methods 0.000 description 21
150000003839 salts Chemical class 0.000 description 20
239000012901 Milli-Q water Substances 0.000 description 19
239000002253 acid Substances 0.000 description 19
230000008859 change Effects 0.000 description 19
238000011049 filling Methods 0.000 description 19
238000005259 measurement Methods 0.000 description 19
230000009467 reduction Effects 0.000 description 19
230000008569 process Effects 0.000 description 18
239000000443 aerosol Substances 0.000 description 17
239000000306 component Substances 0.000 description 17
239000012528 membrane Substances 0.000 description 17
108090000765 processed proteins & peptides Proteins 0.000 description 16
238000000108 ultra-filtration Methods 0.000 description 16
235000001014 amino acid Nutrition 0.000 description 15
229940024606 amino acid Drugs 0.000 description 14
150000001413 amino acids Chemical class 0.000 description 14
239000000463 material Substances 0.000 description 14
238000002360 preparation method Methods 0.000 description 14
239000000126 substance Substances 0.000 description 14
108060003951 Immunoglobulin Proteins 0.000 description 13
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 13
230000002776 aggregation Effects 0.000 description 13
238000004220 aggregation Methods 0.000 description 13
238000000502 dialysis Methods 0.000 description 13
238000010790 dilution Methods 0.000 description 13
239000012895 dilution Substances 0.000 description 13
230000000694 effects Effects 0.000 description 13
238000007710 freezing Methods 0.000 description 13
230000008014 freezing Effects 0.000 description 13
102000018358 immunoglobulin Human genes 0.000 description 13
239000000825 pharmaceutical preparation Substances 0.000 description 13
238000012545 processing Methods 0.000 description 13
238000005070 sampling Methods 0.000 description 13
239000004695 Polyether sulfone Substances 0.000 description 12
238000010521 absorption reaction Methods 0.000 description 12
239000000654 additive Substances 0.000 description 12
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
229920006393 polyether sulfone Polymers 0.000 description 12
230000002829 reductive effect Effects 0.000 description 12
238000000926 separation method Methods 0.000 description 12
239000003570 air Substances 0.000 description 11
229940126534 drug product Drugs 0.000 description 11
238000000265 homogenisation Methods 0.000 description 11
102000004196 processed proteins & peptides Human genes 0.000 description 11
108010047041 Complementarity Determining Regions Proteins 0.000 description 10
238000002835 absorbance Methods 0.000 description 10
230000015572 biosynthetic process Effects 0.000 description 10
239000012530 fluid Substances 0.000 description 10
239000011148 porous material Substances 0.000 description 10
238000001556 precipitation Methods 0.000 description 10
238000012360 testing method Methods 0.000 description 10
238000010257 thawing Methods 0.000 description 10
108010021625 Immunoglobulin Fragments Proteins 0.000 description 9
102000008394 Immunoglobulin Fragments Human genes 0.000 description 9
150000001875 compounds Chemical class 0.000 description 9
239000012153 distilled water Substances 0.000 description 9
150000002148 esters Chemical class 0.000 description 9
239000002245 particle Substances 0.000 description 9
239000002244 precipitate Substances 0.000 description 9
230000000717 retained effect Effects 0.000 description 9
239000011550 stock solution Substances 0.000 description 9
210000004885 white matter Anatomy 0.000 description 9
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 8
230000008901 benefit Effects 0.000 description 8
230000000295 complement effect Effects 0.000 description 8
230000007423 decrease Effects 0.000 description 8
239000011521 glass Substances 0.000 description 8
210000004408 hybridoma Anatomy 0.000 description 8
239000011347 resin Substances 0.000 description 8
229920005989 resin Polymers 0.000 description 8
235000000346 sugar Nutrition 0.000 description 8
238000012546 transfer Methods 0.000 description 8
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
230000000996 additive effect Effects 0.000 description 7
210000003969 blast cell Anatomy 0.000 description 7
230000007717 exclusion Effects 0.000 description 7
238000000605 extraction Methods 0.000 description 7
239000000706 filtrate Substances 0.000 description 7
230000006870 function Effects 0.000 description 7
229920002521 macromolecule Polymers 0.000 description 7
230000014759 maintenance of location Effects 0.000 description 7
229920001184 polypeptide Polymers 0.000 description 7
229910000162 sodium phosphate Inorganic materials 0.000 description 7
235000011008 sodium phosphates Nutrition 0.000 description 7
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 7
238000000870 ultraviolet spectroscopy Methods 0.000 description 7
HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 6
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
102000004190 Enzymes Human genes 0.000 description 6
108090000790 Enzymes Proteins 0.000 description 6
102100032341 PCNA-interacting partner Human genes 0.000 description 6
101710196737 PCNA-interacting partner Proteins 0.000 description 6
108700012920 TNF Proteins 0.000 description 6
238000004925 denaturation Methods 0.000 description 6
230000036425 denaturation Effects 0.000 description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
229910000397 disodium phosphate Inorganic materials 0.000 description 6
229940088598 enzyme Drugs 0.000 description 6
230000014509 gene expression Effects 0.000 description 6
230000003993 interaction Effects 0.000 description 6
150000002500 ions Chemical class 0.000 description 6
230000007774 longterm Effects 0.000 description 6
210000004072 lung Anatomy 0.000 description 6
102000039446 nucleic acids Human genes 0.000 description 6
108020004707 nucleic acids Proteins 0.000 description 6
150000007523 nucleic acids Chemical class 0.000 description 6
230000003287 optical effect Effects 0.000 description 6
230000001681 protective effect Effects 0.000 description 6
108020003175 receptors Proteins 0.000 description 6
102000005962 receptors Human genes 0.000 description 6
230000029058 respiratory gaseous exchange Effects 0.000 description 6
239000012465 retentate Substances 0.000 description 6
239000001488 sodium phosphate Substances 0.000 description 6
239000000725 suspension Substances 0.000 description 6
238000011179 visual inspection Methods 0.000 description 6
241000283073 Equus caballus Species 0.000 description 5
102000008100 Human Serum Albumin Human genes 0.000 description 5
108091006905 Human Serum Albumin Proteins 0.000 description 5
241000699666 Mus <mouse, genus> Species 0.000 description 5
206010036790 Productive cough Diseases 0.000 description 5
238000004364 calculation method Methods 0.000 description 5
230000015556 catabolic process Effects 0.000 description 5
238000004113 cell culture Methods 0.000 description 5
238000012512 characterization method Methods 0.000 description 5
238000006731 degradation reaction Methods 0.000 description 5
230000001419 dependent effect Effects 0.000 description 5
238000001514 detection method Methods 0.000 description 5
238000011161 development Methods 0.000 description 5
201000010099 disease Diseases 0.000 description 5
230000009977 dual effect Effects 0.000 description 5
210000002308 embryonic cell Anatomy 0.000 description 5
238000011156 evaluation Methods 0.000 description 5
235000013305 food Nutrition 0.000 description 5
230000004927 fusion Effects 0.000 description 5
238000004128 high performance liquid chromatography Methods 0.000 description 5
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 5
238000002955 isolation Methods 0.000 description 5
239000011777 magnesium Substances 0.000 description 5
235000013336 milk Nutrition 0.000 description 5
239000008267 milk Substances 0.000 description 5
210000004080 milk Anatomy 0.000 description 5
229920005644 polyethylene terephthalate glycol copolymer Polymers 0.000 description 5
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 5
229920000053 polysorbate 80 Polymers 0.000 description 5
230000004845 protein aggregation Effects 0.000 description 5
239000012488 sample solution Substances 0.000 description 5
239000002904 solvent Substances 0.000 description 5
208000024794 sputum Diseases 0.000 description 5
239000007858 starting material Substances 0.000 description 5
230000032258 transport Effects 0.000 description 5
238000013060 ultrafiltration and diafiltration Methods 0.000 description 5
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
DFUSDJMZWQVQSF-XLGIIRLISA-N (2r)-2-methyl-2-[(4r,8r)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-ol Chemical compound OC1=CC=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 DFUSDJMZWQVQSF-XLGIIRLISA-N 0.000 description 4
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 4
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
238000012369 In process control Methods 0.000 description 4
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
241001465754 Metazoa Species 0.000 description 4
241000699670 Mus sp. Species 0.000 description 4
108010025020 Nerve Growth Factor Proteins 0.000 description 4
ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 4
101710166307 Protein lines Proteins 0.000 description 4
230000009471 action Effects 0.000 description 4
125000000539 amino acid group Chemical group 0.000 description 4
239000002775 capsule Substances 0.000 description 4
238000005341 cation exchange Methods 0.000 description 4
239000003153 chemical reaction reagent Substances 0.000 description 4
235000015165 citric acid Nutrition 0.000 description 4
238000007865 diluting Methods 0.000 description 4
238000009826 distribution Methods 0.000 description 4
238000010965 in-process control Methods 0.000 description 4
230000035772 mutation Effects 0.000 description 4
239000006199 nebulizer Substances 0.000 description 4
238000011022 operating instruction Methods 0.000 description 4
229920001223 polyethylene glycol Polymers 0.000 description 4
230000006798 recombination Effects 0.000 description 4
238000005215 recombination Methods 0.000 description 4
230000000241 respiratory effect Effects 0.000 description 4
238000012216 screening Methods 0.000 description 4
229910052938 sodium sulfate Inorganic materials 0.000 description 4
GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 4
235000011152 sodium sulphate Nutrition 0.000 description 4
238000010561 standard procedure Methods 0.000 description 4
210000002784 stomach Anatomy 0.000 description 4
150000008163 sugars Chemical class 0.000 description 4
208000024891 symptom Diseases 0.000 description 4
238000011144 upstream manufacturing Methods 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
230000005653 Brownian motion process Effects 0.000 description 3
239000004322 Butylated hydroxytoluene Substances 0.000 description 3
NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 3
LERNTVKEWCAPOY-VOGVJGKGSA-N C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 Chemical compound C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 LERNTVKEWCAPOY-VOGVJGKGSA-N 0.000 description 3
108091026890 Coding region Proteins 0.000 description 3
108010000912 Egg Proteins Proteins 0.000 description 3
102000002322 Egg Proteins Human genes 0.000 description 3
CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 description 3
101000690301 Homo sapiens Aldo-keto reductase family 1 member C4 Proteins 0.000 description 3
101001116548 Homo sapiens Protein CBFA2T1 Proteins 0.000 description 3
101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 3
108700005091 Immunoglobulin Genes Proteins 0.000 description 3
102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 3
108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 3
108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 3
102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 3
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 3
125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 3
239000004472 Lysine Substances 0.000 description 3
241000124008 Mammalia Species 0.000 description 3
102000007072 Nerve Growth Factors Human genes 0.000 description 3
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
239000001888 Peptone Substances 0.000 description 3
108010080698 Peptones Proteins 0.000 description 3
229920005654 Sephadex Polymers 0.000 description 3
239000012507 Sephadex™ Substances 0.000 description 3
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 3
150000007513 acids Chemical class 0.000 description 3
YAJCHEVQCOHZDC-QMMNLEPNSA-N actrapid Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3N=CNC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@H](C)CC)[C@H](C)CC)[C@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C(N)=O)C1=CNC=N1 YAJCHEVQCOHZDC-QMMNLEPNSA-N 0.000 description 3
125000003275 alpha amino acid group Chemical group 0.000 description 3
235000006708 antioxidants Nutrition 0.000 description 3
230000009286 beneficial effect Effects 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
238000005537 brownian motion Methods 0.000 description 3
239000000337 buffer salt Substances 0.000 description 3
235000010354 butylated hydroxytoluene Nutrition 0.000 description 3
229940095259 butylated hydroxytoluene Drugs 0.000 description 3
238000004587 chromatography analysis Methods 0.000 description 3
238000011035 continuous diafiltration Methods 0.000 description 3
238000007796 conventional method Methods 0.000 description 3
238000001816 cooling Methods 0.000 description 3
GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
239000008367 deionised water Substances 0.000 description 3
229910021641 deionized water Inorganic materials 0.000 description 3
238000004090 dissolution Methods 0.000 description 3
238000001035 drying Methods 0.000 description 3
239000013020 final formulation Substances 0.000 description 3
239000007789 gas Substances 0.000 description 3
210000004602 germ cell Anatomy 0.000 description 3
235000011187 glycerol Nutrition 0.000 description 3
238000010438 heat treatment Methods 0.000 description 3
102000054751 human RUNX1T1 Human genes 0.000 description 3
210000000987 immune system Anatomy 0.000 description 3
230000016784 immunoglobulin production Effects 0.000 description 3
230000009878 intermolecular interaction Effects 0.000 description 3
230000000670 limiting effect Effects 0.000 description 3
239000012669 liquid formulation Substances 0.000 description 3
231100000350 mutagenesis Toxicity 0.000 description 3
238000002703 mutagenesis Methods 0.000 description 3
230000003647 oxidation Effects 0.000 description 3
238000007254 oxidation reaction Methods 0.000 description 3
150000002923 oximes Chemical class 0.000 description 3
235000019319 peptone Nutrition 0.000 description 3
229920001993 poloxamer 188 Polymers 0.000 description 3
229940044519 poloxamer 188 Drugs 0.000 description 3
229920000136 polysorbate Polymers 0.000 description 3
230000006920 protein precipitation Effects 0.000 description 3
238000011160 research Methods 0.000 description 3
230000004044 response Effects 0.000 description 3
230000002441 reversible effect Effects 0.000 description 3
150000003384 small molecules Chemical class 0.000 description 3
239000007787 solid Substances 0.000 description 3
210000003802 sputum Anatomy 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
229960000257 tiotropium bromide Drugs 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
230000009261 transgenic effect Effects 0.000 description 3
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 2
YVYKOQWMJZXRRM-PUFIMZNGSA-N 3-dehydroshikimate Chemical compound O[C@@H]1C[C@H](C(O)=O)C=C(O)[C@@H]1O YVYKOQWMJZXRRM-PUFIMZNGSA-N 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
239000004475 Arginine Substances 0.000 description 2
102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 2
108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 2
108010009575 CD55 Antigens Proteins 0.000 description 2
108010071942 Colony-Stimulating Factors Proteins 0.000 description 2
102000007644 Colony-Stimulating Factors Human genes 0.000 description 2
SLWWJZMPHJJOPH-UHFFFAOYSA-N DHS Natural products OC1CC(C(O)=O)=CC(=O)C1O SLWWJZMPHJJOPH-UHFFFAOYSA-N 0.000 description 2
108020004414 DNA Proteins 0.000 description 2
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 description 2
108090000394 Erythropoietin Proteins 0.000 description 2
102000003951 Erythropoietin Human genes 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
108010044091 Globulins Proteins 0.000 description 2
235000010469 Glycine max Nutrition 0.000 description 2
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
241000282412 Homo Species 0.000 description 2
108010000521 Human Growth Hormone Proteins 0.000 description 2
102000002265 Human Growth Hormone Human genes 0.000 description 2
239000000854 Human Growth Hormone Substances 0.000 description 2
102000013463 Immunoglobulin Light Chains Human genes 0.000 description 2
108010065825 Immunoglobulin Light Chains Proteins 0.000 description 2
108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
102000004877 Insulin Human genes 0.000 description 2
108090001061 Insulin Proteins 0.000 description 2
108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 2
102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 2
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 2
239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 2
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
238000013494 PH determination Methods 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
108010001014 Plasminogen Activators Proteins 0.000 description 2
102000001938 Plasminogen Activators Human genes 0.000 description 2
108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
241000276498 Pollachius virens Species 0.000 description 2
229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
239000004698 Polyethylene Substances 0.000 description 2
239000004721 Polyphenylene oxide Substances 0.000 description 2
229920001213 Polysorbate 20 Polymers 0.000 description 2
201000004681 Psoriasis Diseases 0.000 description 2
208000001431 Psychomotor Agitation Diseases 0.000 description 2
206010038743 Restlessness Diseases 0.000 description 2
241000283984 Rodentia Species 0.000 description 2
102000007562 Serum Albumin Human genes 0.000 description 2
108010071390 Serum Albumin Proteins 0.000 description 2
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 2
LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 2
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
108010009583 Transforming Growth Factors Proteins 0.000 description 2
102000009618 Transforming Growth Factors Human genes 0.000 description 2
102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 2
108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 2
108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
230000002411 adverse Effects 0.000 description 2
150000005215 alkyl ethers Chemical class 0.000 description 2
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
230000000890 antigenic effect Effects 0.000 description 2
238000013459 approach Methods 0.000 description 2
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
238000000149 argon plasma sintering Methods 0.000 description 2
235000010323 ascorbic acid Nutrition 0.000 description 2
239000011668 ascorbic acid Substances 0.000 description 2
229960005070 ascorbic acid Drugs 0.000 description 2
235000010385 ascorbyl palmitate Nutrition 0.000 description 2
238000003556 assay Methods 0.000 description 2
239000011324 bead Substances 0.000 description 2
230000008033 biological extinction Effects 0.000 description 2
230000005540 biological transmission Effects 0.000 description 2
235000020958 biotin Nutrition 0.000 description 2
239000011616 biotin Substances 0.000 description 2
229960002685 biotin Drugs 0.000 description 2
229940112869 bone morphogenetic protein Drugs 0.000 description 2
229940094657 botulinum toxin type a Drugs 0.000 description 2
239000012482 calibration solution Substances 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
238000005277 cation exchange chromatography Methods 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
239000007979 citrate buffer Substances 0.000 description 2
238000005097 cold rolling Methods 0.000 description 2
238000012885 constant function Methods 0.000 description 2
239000000356 contaminant Substances 0.000 description 2
238000004132 cross linking Methods 0.000 description 2
239000003431 cross linking reagent Substances 0.000 description 2
238000002425 crystallisation Methods 0.000 description 2
230000008025 crystallization Effects 0.000 description 2
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
230000006378 damage Effects 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
238000013461 design Methods 0.000 description 2
239000003599 detergent Substances 0.000 description 2
239000000539 dimer Substances 0.000 description 2
238000011038 discontinuous diafiltration by volume reduction Methods 0.000 description 2
238000012377 drug delivery Methods 0.000 description 2
239000013583 drug formulation Substances 0.000 description 2
239000000428 dust Substances 0.000 description 2
239000002532 enzyme inhibitor Substances 0.000 description 2
229940125532 enzyme inhibitor Drugs 0.000 description 2
229940105423 erythropoietin Drugs 0.000 description 2
210000003527 eukaryotic cell Anatomy 0.000 description 2
239000013604 expression vector Substances 0.000 description 2
238000001914 filtration Methods 0.000 description 2
OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
235000010855 food raising agent Nutrition 0.000 description 2
239000001530 fumaric acid Substances 0.000 description 2
108020001507 fusion proteins Proteins 0.000 description 2
102000037865 fusion proteins Human genes 0.000 description 2
239000000499 gel Substances 0.000 description 2
238000002523 gelfiltration Methods 0.000 description 2
239000003102 growth factor Substances 0.000 description 2
230000036541 health Effects 0.000 description 2
229940088597 hormone Drugs 0.000 description 2
239000005556 hormone Substances 0.000 description 2
235000011167 hydrochloric acid Nutrition 0.000 description 2
HIFJCPQKFCZDDL-ACWOEMLNSA-N iloprost Chemical compound C1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)C(C)CC#CC)[C@H](O)C[C@@H]21 HIFJCPQKFCZDDL-ACWOEMLNSA-N 0.000 description 2
230000001900 immune effect Effects 0.000 description 2
238000002649 immunization Methods 0.000 description 2
230000005847 immunogenicity Effects 0.000 description 2
230000002637 immunotoxin Effects 0.000 description 2
239000002596 immunotoxin Substances 0.000 description 2
231100000608 immunotoxin Toxicity 0.000 description 2
229940051026 immunotoxin Drugs 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
230000008595 infiltration Effects 0.000 description 2
238000001764 infiltration Methods 0.000 description 2
230000003434 inspiratory effect Effects 0.000 description 2
238000005342 ion exchange Methods 0.000 description 2
229910052742 iron Inorganic materials 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
239000008101 lactose Substances 0.000 description 2
238000011031 large-scale manufacturing process Methods 0.000 description 2
210000000265 leukocyte Anatomy 0.000 description 2
239000003446 ligand Substances 0.000 description 2
229910052943 magnesium sulfate Inorganic materials 0.000 description 2
235000019341 magnesium sulphate Nutrition 0.000 description 2
239000001630 malic acid Substances 0.000 description 2
235000011090 malic acid Nutrition 0.000 description 2
239000003550 marker Substances 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
229930182817 methionine Natural products 0.000 description 2
238000002156 mixing Methods 0.000 description 2
YKQOSKADJPQZHB-QNPLFGSASA-N n-[(1s)-3-amino-1-{[(1s,2r)-1-{[(1s)-3-amino-1-{[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptaazacyclotricosan-21-yl]carbamoyl}propyl]carbamoyl}-2- Chemical compound CCC(C)CCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O YKQOSKADJPQZHB-QNPLFGSASA-N 0.000 description 2
239000003900 neurotrophic factor Substances 0.000 description 2
230000003472 neutralizing effect Effects 0.000 description 2
238000005457 optimization Methods 0.000 description 2
238000010979 pH adjustment Methods 0.000 description 2
230000037361 pathway Effects 0.000 description 2
230000035515 penetration Effects 0.000 description 2
229940127557 pharmaceutical product Drugs 0.000 description 2
229940127126 plasminogen activator Drugs 0.000 description 2
239000004033 plastic Substances 0.000 description 2
229920003023 plastic Polymers 0.000 description 2
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
229920001983 poloxamer Polymers 0.000 description 2
229920003229 poly(methyl methacrylate) Polymers 0.000 description 2
239000004417 polycarbonate Substances 0.000 description 2
229920000570 polyether Polymers 0.000 description 2
229920000573 polyethylene Polymers 0.000 description 2
239000004926 polymethyl methacrylate Substances 0.000 description 2
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
239000000473 propyl gallate Substances 0.000 description 2
235000010388 propyl gallate Nutrition 0.000 description 2
229940075579 propyl gallate Drugs 0.000 description 2
238000005086 pumping Methods 0.000 description 2
238000010188 recombinant method Methods 0.000 description 2
239000004627 regenerated cellulose Substances 0.000 description 2
206010039073 rheumatoid arthritis Diseases 0.000 description 2
238000010583 slow cooling Methods 0.000 description 2
239000001509 sodium citrate Substances 0.000 description 2
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 2
239000012312 sodium hydride Substances 0.000 description 2
229910000104 sodium hydride Inorganic materials 0.000 description 2
235000010267 sodium hydrogen sulphite Nutrition 0.000 description 2
229940001584 sodium metabisulfite Drugs 0.000 description 2
235000010262 sodium metabisulphite Nutrition 0.000 description 2
235000010265 sodium sulphite Nutrition 0.000 description 2
238000001179 sorption measurement Methods 0.000 description 2
238000002798 spectrophotometry method Methods 0.000 description 2
150000003431 steroids Chemical class 0.000 description 2
239000000758 substrate Substances 0.000 description 2
239000013589 supplement Substances 0.000 description 2
239000011975 tartaric acid Substances 0.000 description 2
235000002906 tartaric acid Nutrition 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
230000014616 translation Effects 0.000 description 2
239000002753 trypsin inhibitor Substances 0.000 description 2
229960005356 urokinase Drugs 0.000 description 2
239000000052 vinegar Substances 0.000 description 2
235000021419 vinegar Nutrition 0.000 description 2
SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
HSTZMXCBWJGKHG-UHFFFAOYSA-N (E)-piceid Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=CC(C=CC=2C=CC(O)=CC=2)=C1 HSTZMXCBWJGKHG-UHFFFAOYSA-N 0.000 description 1
FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
AHJCTAYXMOPNNT-UHFFFAOYSA-N 3-hydroxy-2-phenylchromene-4-thione Chemical compound O1C2=CC=CC=C2C(=S)C(O)=C1C1=CC=CC=C1 AHJCTAYXMOPNNT-UHFFFAOYSA-N 0.000 description 1
HCFAJYNVAYBARA-UHFFFAOYSA-N 4-heptanone Chemical class CCCC(=O)CCC HCFAJYNVAYBARA-UHFFFAOYSA-N 0.000 description 1
241000208140 Acer Species 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
206010069754 Acquired gene mutation Diseases 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
WZPBZJONDBGPKJ-UHFFFAOYSA-N Antibiotic SQ 26917 Natural products O=C1N(S(O)(=O)=O)C(C)C1NC(=O)C(=NOC(C)(C)C(O)=O)C1=CSC(N)=N1 WZPBZJONDBGPKJ-UHFFFAOYSA-N 0.000 description 1
240000005528 Arctium lappa Species 0.000 description 1
235000003130 Arctium lappa Nutrition 0.000 description 1
235000008078 Arctium minus Nutrition 0.000 description 1
101800001288 Atrial natriuretic factor Proteins 0.000 description 1
102400001282 Atrial natriuretic peptide Human genes 0.000 description 1
101800001890 Atrial natriuretic peptide Proteins 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
108090001008 Avidin Proteins 0.000 description 1
102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
241001674044 Blattodea Species 0.000 description 1
102000015081 Blood Coagulation Factors Human genes 0.000 description 1
108010039209 Blood Coagulation Factors Proteins 0.000 description 1
208000031872 Body Remains Diseases 0.000 description 1
108030001720 Bontoxilysin Proteins 0.000 description 1
ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
102100031092 C-C motif chemokine 3 Human genes 0.000 description 1
101710155856 C-C motif chemokine 3 Proteins 0.000 description 1
102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 1
101100279436 Caenorhabditis elegans egg-2 gene Proteins 0.000 description 1
101100512078 Caenorhabditis elegans lys-1 gene Proteins 0.000 description 1
101100129088 Caenorhabditis elegans lys-2 gene Proteins 0.000 description 1
102400000113 Calcitonin Human genes 0.000 description 1
108060001064 Calcitonin Proteins 0.000 description 1
239000002970 Calcium lactobionate Substances 0.000 description 1
208000003643 Callosities Diseases 0.000 description 1
241000282465 Canis Species 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
241000283707 Capra Species 0.000 description 1
102000014914 Carrier Proteins Human genes 0.000 description 1
108010078791 Carrier Proteins Proteins 0.000 description 1
206010068051 Chimerism Diseases 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
229920002567 Chondroitin Polymers 0.000 description 1
VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
OMPIYDSYGYKWSG-UHFFFAOYSA-N Citronensaeure-alpha-aethylester Natural products CCOC(=O)CC(O)(C(O)=O)CC(O)=O OMPIYDSYGYKWSG-UHFFFAOYSA-N 0.000 description 1
235000005979 Citrus limon Nutrition 0.000 description 1
244000131522 Citrus pyriformis Species 0.000 description 1
102100022641 Coagulation factor IX Human genes 0.000 description 1
206010053567 Coagulopathies Diseases 0.000 description 1
206010009944 Colon cancer Diseases 0.000 description 1
240000003890 Commiphora wightii Species 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
102000015792 Cyclin-Dependent Kinase 2 Human genes 0.000 description 1
108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 1
ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
108010053770 Deoxyribonucleases Proteins 0.000 description 1
102000016911 Deoxyribonucleases Human genes 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
MWRWFPQBGSZWNV-UHFFFAOYSA-N Dinitrosopentamethylenetetramine Chemical compound C1N2CN(N=O)CN1CN(N=O)C2 MWRWFPQBGSZWNV-UHFFFAOYSA-N 0.000 description 1
241000283086 Equidae Species 0.000 description 1
241001331845 Equus asinus x caballus Species 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
101100400218 Escherichia coli (strain K12) lysO gene Proteins 0.000 description 1
241000206602 Eukaryota Species 0.000 description 1
108010076282 Factor IX Proteins 0.000 description 1
108010054218 Factor VIII Proteins 0.000 description 1
102000001690 Factor VIII Human genes 0.000 description 1
108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
206010016654 Fibrosis Diseases 0.000 description 1
102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
102000006395 Globulins Human genes 0.000 description 1
102400000321 Glucagon Human genes 0.000 description 1
108060003199 Glucagon Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
244000068988 Glycine max Species 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
102000006771 Gonadotropins Human genes 0.000 description 1
108010086677 Gonadotropins Proteins 0.000 description 1
108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
108010051696 Growth Hormone Proteins 0.000 description 1
102000018997 Growth Hormone Human genes 0.000 description 1
239000000095 Growth Hormone-Releasing Hormone Substances 0.000 description 1
SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
101001002634 Homo sapiens Interleukin-1 alpha Proteins 0.000 description 1
101000960954 Homo sapiens Interleukin-18 Proteins 0.000 description 1
101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 1
101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
102000003839 Human Proteins Human genes 0.000 description 1
108090000144 Human Proteins Proteins 0.000 description 1
206010020649 Hyperkeratosis Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010021703 Indifference Diseases 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
102100020881 Interleukin-1 alpha Human genes 0.000 description 1
102100026018 Interleukin-1 receptor antagonist protein Human genes 0.000 description 1
101710144554 Interleukin-1 receptor antagonist protein Proteins 0.000 description 1
108010082786 Interleukin-1alpha Proteins 0.000 description 1
206010058031 Joint adhesion Diseases 0.000 description 1
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
241000735234 Ligustrum Species 0.000 description 1
108090001030 Lipoproteins Proteins 0.000 description 1
102000004895 Lipoproteins Human genes 0.000 description 1
208000032376 Lung infection Diseases 0.000 description 1
102000009151 Luteinizing Hormone Human genes 0.000 description 1
108010073521 Luteinizing Hormone Proteins 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
102000009571 Macrophage Inflammatory Proteins Human genes 0.000 description 1
108010009474 Macrophage Inflammatory Proteins Proteins 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 description 1
102000016943 Muramidase Human genes 0.000 description 1
108010014251 Muramidase Proteins 0.000 description 1
241001529936 Murinae Species 0.000 description 1
108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
229920002274 Nalgene Polymers 0.000 description 1
108090000028 Neprilysin Proteins 0.000 description 1
102000003729 Neprilysin Human genes 0.000 description 1
241000183666 Nepsera aquatica Species 0.000 description 1
102000015336 Nerve Growth Factor Human genes 0.000 description 1
102100029268 Neurotrophin-3 Human genes 0.000 description 1
108091028043 Nucleic acid sequence Proteins 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
239000002033 PVDF binder Substances 0.000 description 1
241000282320 Panthera leo Species 0.000 description 1
108090000526 Papain Proteins 0.000 description 1
102000003982 Parathyroid hormone Human genes 0.000 description 1
108090000445 Parathyroid hormone Proteins 0.000 description 1
101150034459 Parpbp gene Proteins 0.000 description 1
241001494479 Pecora Species 0.000 description 1
102000057297 Pepsin A Human genes 0.000 description 1
108090000284 Pepsin A Proteins 0.000 description 1
RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
229920002675 Polyoxyl Polymers 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 description 1
108010076181 Proinsulin Proteins 0.000 description 1
239000004365 Protease Substances 0.000 description 1
101800004937 Protein C Proteins 0.000 description 1
102000017975 Protein C Human genes 0.000 description 1
101710089165 Protein white Proteins 0.000 description 1
244000018633 Prunus armeniaca Species 0.000 description 1
235000009827 Prunus armeniaca Nutrition 0.000 description 1
208000003251 Pruritus Diseases 0.000 description 1
241000589517 Pseudomonas aeruginosa Species 0.000 description 1
206010037742 Rabies Diseases 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
208000025747 Rheumatic disease Diseases 0.000 description 1
KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 1
108091006629 SLC13A2 Proteins 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
101800001700 Saposin-D Proteins 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
102100022831 Somatoliberin Human genes 0.000 description 1
101710142969 Somatoliberin Proteins 0.000 description 1
244000062793 Sorghum vulgare Species 0.000 description 1
208000006045 Spondylarthropathies Diseases 0.000 description 1
229910000831 Steel Inorganic materials 0.000 description 1
108010090804 Streptavidin Proteins 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
241000282887 Suidae Species 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
102000019197 Superoxide Dismutase Human genes 0.000 description 1
108010012715 Superoxide dismutase Proteins 0.000 description 1
102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
101150109894 TGFA gene Proteins 0.000 description 1
102100033213 Teneurin-1 Human genes 0.000 description 1
108090000190 Thrombin Proteins 0.000 description 1
108010000499 Thromboplastin Proteins 0.000 description 1
102000002262 Thromboplastin Human genes 0.000 description 1
102000011923 Thyrotropin Human genes 0.000 description 1
108010061174 Thyrotropin Proteins 0.000 description 1
DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
101710162629 Trypsin inhibitor Proteins 0.000 description 1
229940122618 Trypsin inhibitor Drugs 0.000 description 1
108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
241000700605 Viruses Species 0.000 description 1
FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
229930003270 Vitamin B Natural products 0.000 description 1
229930003268 Vitamin C Natural products 0.000 description 1
229930003316 Vitamin D Natural products 0.000 description 1
QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
229930003427 Vitamin E Natural products 0.000 description 1
239000005862 Whey Substances 0.000 description 1
102000007544 Whey Proteins Human genes 0.000 description 1
108010046377 Whey Proteins Proteins 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
240000008042 Zea mays Species 0.000 description 1
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
235000002017 Zea mays subsp mays Nutrition 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
CBUJHSGSOYAVJD-UHFFFAOYSA-N [2-methyl-2-(4,8,12-trimethyltridecyl)-3,4-dihydrochromen-6-yl] acetate Chemical compound CC(=O)OC1=CC=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 CBUJHSGSOYAVJD-UHFFFAOYSA-N 0.000 description 1
KKKNAENNDRVRRC-UHFFFAOYSA-N [S].OCC(O)CO Chemical compound [S].OCC(O)CO KKKNAENNDRVRRC-UHFFFAOYSA-N 0.000 description 1
229940022663 acetate Drugs 0.000 description 1
235000011054 acetic acid Nutrition 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000008186 active pharmaceutical agent Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
230000003044 adaptive effect Effects 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
238000012387 aerosolization Methods 0.000 description 1
229960003227 afelimomab Drugs 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
230000009418 agronomic effect Effects 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
239000012080 ambient air Substances 0.000 description 1
239000010975 amethyst Substances 0.000 description 1
LNTHITQWFMADLM-UHFFFAOYSA-N anhydrous gallic acid Natural products OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 1
125000000129 anionic group Chemical group 0.000 description 1
230000000675 anti-caries Effects 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
229940090047 auto-injector Drugs 0.000 description 1
WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 description 1
229960003644 aztreonam Drugs 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
230000001588 bifunctional effect Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
229920001222 biopolymer Polymers 0.000 description 1
239000003114 blood coagulation factor Substances 0.000 description 1
239000003130 blood coagulation factor inhibitor Substances 0.000 description 1
238000007664 blowing Methods 0.000 description 1
238000006664 bond formation reaction Methods 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
229910052796 boron Inorganic materials 0.000 description 1
229940053031 botulinum toxin Drugs 0.000 description 1
108010006025 bovine growth hormone Proteins 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
239000008364 bulk solution Substances 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
229960004015 calcitonin Drugs 0.000 description 1
FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
239000001354 calcium citrate Substances 0.000 description 1
235000019307 calcium lactobionate Nutrition 0.000 description 1
229940050954 calcium lactobionate Drugs 0.000 description 1
RHEMCSSAABKPLI-SQCCMBKESA-L calcium;(2r,3r,4r,5r)-2,3,5,6-tetrahydroxy-4-[(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexanoate Chemical compound [Ca+2].[O-]C(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O.[O-]C(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O RHEMCSSAABKPLI-SQCCMBKESA-L 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
229940045200 cardioprotective agent Drugs 0.000 description 1
235000021466 carotenoid Nutrition 0.000 description 1
150000001747 carotenoids Chemical class 0.000 description 1
NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
239000012578 cell culture reagent Substances 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
210000004671 cell-free system Anatomy 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
238000005660 chlorination reaction Methods 0.000 description 1
DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
238000013375 chromatographic separation Methods 0.000 description 1
238000011210 chromatographic step Methods 0.000 description 1
239000011651 chromium Substances 0.000 description 1
229910052804 chromium Inorganic materials 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
229950002334 clenoliximab Drugs 0.000 description 1
230000035602 clotting Effects 0.000 description 1
230000004186 co-expression Effects 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
239000005515 coenzyme Substances 0.000 description 1
238000001246 colloidal dispersion Methods 0.000 description 1
208000029742 colonic neoplasm Diseases 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
230000004154 complement system Effects 0.000 description 1
230000009918 complex formation Effects 0.000 description 1
238000013329 compounding Methods 0.000 description 1
239000012468 concentrated sample Substances 0.000 description 1
229920002770 condensed tannin Polymers 0.000 description 1
230000003750 conditioning effect Effects 0.000 description 1
238000010276 construction Methods 0.000 description 1
239000013256 coordination polymer Substances 0.000 description 1
239000008358 core component Substances 0.000 description 1
235000005822 corn Nutrition 0.000 description 1
229960002433 cysteine Drugs 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
229960001305 cysteine hydrochloride Drugs 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
239000007857 degradation product Substances 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
238000001739 density measurement Methods 0.000 description 1
230000006866 deterioration Effects 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
238000002405 diagnostic procedure Methods 0.000 description 1
AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
229960003529 diazepam Drugs 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
230000029087 digestion Effects 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
AIUDWMLXCFRVDR-UHFFFAOYSA-N dimethyl 2-(3-ethyl-3-methylpentyl)propanedioate Chemical class CCC(C)(CC)CCC(C(=O)OC)C(=O)OC AIUDWMLXCFRVDR-UHFFFAOYSA-N 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
239000012738 dissolution medium Substances 0.000 description 1
238000004821 distillation Methods 0.000 description 1
125000002228 disulfide group Chemical group 0.000 description 1
WBZKQQHYRPRKNJ-UHFFFAOYSA-L disulfite Chemical compound [O-]S(=O)S([O-])(=O)=O WBZKQQHYRPRKNJ-UHFFFAOYSA-L 0.000 description 1
238000010889 donnan-equilibrium Methods 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
229960002918 doxorubicin hydrochloride Drugs 0.000 description 1
229940088679 drug related substance Drugs 0.000 description 1
229960001484 edetic acid Drugs 0.000 description 1
239000012636 effector Substances 0.000 description 1
210000002969 egg yolk Anatomy 0.000 description 1
235000013345 egg yolk Nutrition 0.000 description 1
230000005684 electric field Effects 0.000 description 1
230000005611 electricity Effects 0.000 description 1
238000010828 elution Methods 0.000 description 1
210000001163 endosome Anatomy 0.000 description 1
238000006911 enzymatic reaction Methods 0.000 description 1
229940057975 ethyl citrate Drugs 0.000 description 1
229960004222 factor ix Drugs 0.000 description 1
235000019581 fat taste sensations Nutrition 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
239000012526 feed medium Substances 0.000 description 1
239000011790 ferrous sulphate Substances 0.000 description 1
235000003891 ferrous sulphate Nutrition 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
230000004761 fibrosis Effects 0.000 description 1
238000005429 filling process Methods 0.000 description 1
229930003935 flavonoid Natural products 0.000 description 1
150000002215 flavonoids Chemical class 0.000 description 1
235000017173 flavonoids Nutrition 0.000 description 1
238000011010 flushing procedure Methods 0.000 description 1
229960000289 fluticasone propionate Drugs 0.000 description 1
WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 description 1
229960000304 folic acid Drugs 0.000 description 1
235000019152 folic acid Nutrition 0.000 description 1
239000011724 folic acid Substances 0.000 description 1
229940028334 follicle stimulating hormone Drugs 0.000 description 1
239000012537 formulation buffer Substances 0.000 description 1
238000013467 fragmentation Methods 0.000 description 1
238000006062 fragmentation reaction Methods 0.000 description 1
239000003517 fume Substances 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
229950001109 galiximab Drugs 0.000 description 1
210000000232 gallbladder Anatomy 0.000 description 1
229940074391 gallic acid Drugs 0.000 description 1
235000004515 gallic acid Nutrition 0.000 description 1
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
238000003500 gene array Methods 0.000 description 1
210000002980 germ line cell Anatomy 0.000 description 1
102000034238 globular proteins Human genes 0.000 description 1
108091005896 globular proteins Proteins 0.000 description 1
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
229960004666 glucagon Drugs 0.000 description 1
229960002442 glucosamine Drugs 0.000 description 1
239000002622 gonadotropin Substances 0.000 description 1
239000008187 granular material Substances 0.000 description 1
229940087603 grape seed extract Drugs 0.000 description 1
235000002532 grape seed extract Nutrition 0.000 description 1
230000012010 growth Effects 0.000 description 1
239000000122 growth hormone Substances 0.000 description 1
239000001307 helium Substances 0.000 description 1
229910052734 helium Inorganic materials 0.000 description 1
SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
239000000833 heterodimer Substances 0.000 description 1
239000008241 heterogeneous mixture Substances 0.000 description 1
210000000003 hoof Anatomy 0.000 description 1
102000043959 human IL18 Human genes 0.000 description 1
150000002429 hydrazines Chemical class 0.000 description 1
GBHRVZIGDIUCJB-UHFFFAOYSA-N hydrogenphosphite Chemical compound OP([O-])[O-] GBHRVZIGDIUCJB-UHFFFAOYSA-N 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
125000004356 hydroxy functional group Chemical group O* 0.000 description 1
239000005457 ice water Substances 0.000 description 1
229960002240 iloprost Drugs 0.000 description 1
150000002466 imines Chemical class 0.000 description 1
230000036039 immunity Effects 0.000 description 1
230000003053 immunization Effects 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
230000003116 impacting effect Effects 0.000 description 1
239000012535 impurity Substances 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
208000014674 injury Diseases 0.000 description 1
CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
229960000367 inositol Drugs 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
102000028416 insulin-like growth factor binding Human genes 0.000 description 1
108091022911 insulin-like growth factor binding Proteins 0.000 description 1
102000006495 integrins Human genes 0.000 description 1
108010044426 integrins Proteins 0.000 description 1
229940047124 interferons Drugs 0.000 description 1
208000028774 intestinal disease Diseases 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
238000007919 intrasynovial administration Methods 0.000 description 1
238000007913 intrathecal administration Methods 0.000 description 1
230000037427 ion transport Effects 0.000 description 1
BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
230000007794 irritation Effects 0.000 description 1
FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
229940090046 jet injector Drugs 0.000 description 1
238000005304 joining Methods 0.000 description 1
229950010828 keliximab Drugs 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
239000010985 leather Substances 0.000 description 1
229960004194 lidocaine Drugs 0.000 description 1
AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 description 1
235000019136 lipoic acid Nutrition 0.000 description 1
238000013123 lung function test Methods 0.000 description 1
239000003580 lung surfactant Substances 0.000 description 1
229940040129 luteinizing hormone Drugs 0.000 description 1
230000002934 lysing effect Effects 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
238000013507 mapping Methods 0.000 description 1
235000006109 methionine Nutrition 0.000 description 1
238000004452 microanalysis Methods 0.000 description 1
239000011859 microparticle Substances 0.000 description 1
235000019713 millet Nutrition 0.000 description 1
239000003595 mist Substances 0.000 description 1
239000003068 molecular probe Substances 0.000 description 1
229940045641 monobasic sodium phosphate Drugs 0.000 description 1
229910000403 monosodium phosphate Inorganic materials 0.000 description 1
235000019799 monosodium phosphate Nutrition 0.000 description 1
PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
231100000219 mutagenic Toxicity 0.000 description 1
230000003505 mutagenic effect Effects 0.000 description 1
239000002105 nanoparticle Substances 0.000 description 1
229940053128 nerve growth factor Drugs 0.000 description 1
230000000926 neurological effect Effects 0.000 description 1
229960002715 nicotine Drugs 0.000 description 1
SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
229960003512 nicotinic acid Drugs 0.000 description 1
235000001968 nicotinic acid Nutrition 0.000 description 1
239000011664 nicotinic acid Substances 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
229910052762 osmium Inorganic materials 0.000 description 1
SYQBFIAQOQZEGI-UHFFFAOYSA-N osmium atom Chemical compound [Os] SYQBFIAQOQZEGI-UHFFFAOYSA-N 0.000 description 1
230000002138 osteoinductive effect Effects 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
229950007318 ozogamicin Drugs 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
229940055729 papain Drugs 0.000 description 1
235000019834 papain Nutrition 0.000 description 1
239000000199 parathyroid hormone Substances 0.000 description 1
229960001319 parathyroid hormone Drugs 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
YIYBQIKDCADOSF-UHFFFAOYSA-N pent-2-enoic acid Chemical compound CCC=CC(O)=O YIYBQIKDCADOSF-UHFFFAOYSA-N 0.000 description 1
229940111202 pepsin Drugs 0.000 description 1
238000010647 peptide synthesis reaction Methods 0.000 description 1
229940066779 peptones Drugs 0.000 description 1
230000010412 perfusion Effects 0.000 description 1
WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
229940068065 phytosterols Drugs 0.000 description 1
235000018192 pine bark supplement Nutrition 0.000 description 1
229910052697 platinum Inorganic materials 0.000 description 1
229920001992 poloxamer 407 Polymers 0.000 description 1
229940044476 poloxamer 407 Drugs 0.000 description 1
229920000515 polycarbonate Polymers 0.000 description 1
229960003764 polydatin Drugs 0.000 description 1
239000008389 polyethoxylated castor oil Substances 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
238000003752 polymerase chain reaction Methods 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
229920002981 polyvinylidene fluoride Polymers 0.000 description 1
230000008092 positive effect Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000037452 priming Effects 0.000 description 1
UKPBXIFLSVLDPA-UHFFFAOYSA-N propylhydrazine Chemical compound CCCNN UKPBXIFLSVLDPA-UHFFFAOYSA-N 0.000 description 1
239000003223 protective agent Substances 0.000 description 1
238000000159 protein binding assay Methods 0.000 description 1
229960000856 protein c Drugs 0.000 description 1
239000003531 protein hydrolysate Substances 0.000 description 1
230000009145 protein modification Effects 0.000 description 1
230000007925 protein solubilization Effects 0.000 description 1
238000001799 protein solubilization Methods 0.000 description 1
230000029983 protein stabilization Effects 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
239000008213 purified water Substances 0.000 description 1
229940106796 pycnogenol Drugs 0.000 description 1
238000003908 quality control method Methods 0.000 description 1
239000010453 quartz Substances 0.000 description 1
239000001397 quillaja saponaria molina bark Substances 0.000 description 1
230000006340 racemization Effects 0.000 description 1
238000003259 recombinant expression Methods 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
210000002345 respiratory system Anatomy 0.000 description 1
238000001223 reverse osmosis Methods 0.000 description 1
238000012552 review Methods 0.000 description 1
230000000552 rheumatic effect Effects 0.000 description 1
229910052707 ruthenium Inorganic materials 0.000 description 1
HNMATTJJEPZZMM-BPKVFSPJSA-N s-[(2r,3s,4s,6s)-6-[[(2r,3s,4s,5r,6r)-5-[(2s,4s,5s)-5-[acetyl(ethyl)amino]-4-methoxyoxan-2-yl]oxy-6-[[(2s,5z,9r,13e)-13-[2-[[4-[(2e)-2-[1-[4-(4-amino-4-oxobutoxy)phenyl]ethylidene]hydrazinyl]-2-methyl-4-oxobutan-2-yl]disulfanyl]ethylidene]-9-hydroxy-12-(m Chemical compound C1[C@H](OC)[C@@H](N(CC)C(C)=O)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@@](C/3=C/CSSC(C)(C)CC(=O)N\N=C(/C)C=3C=CC(OCCCC(N)=O)=CC=3)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HNMATTJJEPZZMM-BPKVFSPJSA-N 0.000 description 1
229930182490 saponin Natural products 0.000 description 1
150000007949 saponins Chemical class 0.000 description 1
238000013341 scale-up Methods 0.000 description 1
CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
230000028327 secretion Effects 0.000 description 1
239000013049 sediment Substances 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
235000015170 shellfish Nutrition 0.000 description 1
230000037384 skin absorption Effects 0.000 description 1
231100000274 skin absorption Toxicity 0.000 description 1
208000017520 skin disease Diseases 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
235000010378 sodium ascorbate Nutrition 0.000 description 1
PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
229960005055 sodium ascorbate Drugs 0.000 description 1
235000011083 sodium citrates Nutrition 0.000 description 1
AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
JVBXVOWTABLYPX-UHFFFAOYSA-L sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 description 1
229940079827 sodium hydrogen sulfite Drugs 0.000 description 1
SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
239000012064 sodium phosphate buffer Substances 0.000 description 1
229910052979 sodium sulfide Inorganic materials 0.000 description 1
GRVFOGOEDUUMBP-UHFFFAOYSA-N sodium sulfide (anhydrous) Chemical compound [Na+].[Na+].[S-2] GRVFOGOEDUUMBP-UHFFFAOYSA-N 0.000 description 1
PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
DFIWJEVKLWMZBI-UHFFFAOYSA-M sodium;dihydrogen phosphate;phosphoric acid Chemical compound [Na+].OP(O)(O)=O.OP(O)([O-])=O DFIWJEVKLWMZBI-UHFFFAOYSA-M 0.000 description 1
IBUIVNCCBFLEJL-UHFFFAOYSA-M sodium;phosphoric acid;chloride Chemical compound [Na+].[Cl-].OP(O)(O)=O IBUIVNCCBFLEJL-UHFFFAOYSA-M 0.000 description 1
230000037439 somatic mutation Effects 0.000 description 1
201000005671 spondyloarthropathy Diseases 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
239000012086 standard solution Substances 0.000 description 1
238000011272 standard treatment Methods 0.000 description 1
238000010025 steaming Methods 0.000 description 1
239000010959 steel Substances 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
239000004575 stone Substances 0.000 description 1
229940014800 succinic anhydride Drugs 0.000 description 1
DHCDFWKWKRSZHF-UHFFFAOYSA-N sulfurothioic S-acid Chemical compound OS(O)(=O)=S DHCDFWKWKRSZHF-UHFFFAOYSA-N 0.000 description 1
229910021653 sulphate ion Inorganic materials 0.000 description 1
230000009469 supplementation Effects 0.000 description 1
238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
238000010189 synthetic method Methods 0.000 description 1
229960002663 thioctic acid Drugs 0.000 description 1
229960004072 thrombin Drugs 0.000 description 1
RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
230000036962 time dependent Effects 0.000 description 1
235000010384 tocopherol Nutrition 0.000 description 1
229930003799 tocopherol Natural products 0.000 description 1
229960001295 tocopherol Drugs 0.000 description 1
239000011732 tocopherol Substances 0.000 description 1
229940042585 tocopherol acetate Drugs 0.000 description 1
239000003860 topical agent Substances 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
HSTZMXCBWJGKHG-CUYWLFDKSA-N trans-piceid Polymers O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(\C=C\C=2C=CC(O)=CC=2)=C1 HSTZMXCBWJGKHG-CUYWLFDKSA-N 0.000 description 1
230000007704 transition Effects 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
235000013337 tricalcium citrate Nutrition 0.000 description 1
235000013769 triethyl citrate Nutrition 0.000 description 1
238000010977 unit operation Methods 0.000 description 1
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
238000009834 vaporization Methods 0.000 description 1
230000008016 vaporization Effects 0.000 description 1
229940105295 ventavis Drugs 0.000 description 1
230000035899 viability Effects 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
235000019155 vitamin A Nutrition 0.000 description 1
239000011719 vitamin A Substances 0.000 description 1
235000019156 vitamin B Nutrition 0.000 description 1
239000011720 vitamin B Substances 0.000 description 1
235000019154 vitamin C Nutrition 0.000 description 1
239000011718 vitamin C Substances 0.000 description 1
235000019166 vitamin D Nutrition 0.000 description 1
239000011710 vitamin D Substances 0.000 description 1
150000003710 vitamin D derivatives Chemical class 0.000 description 1
235000019165 vitamin E Nutrition 0.000 description 1
229940046009 vitamin E Drugs 0.000 description 1
239000011709 vitamin E Substances 0.000 description 1
229940045997 vitamin a Drugs 0.000 description 1
229940046008 vitamin d Drugs 0.000 description 1
239000001717 vitis vinifera seed extract Substances 0.000 description 1
239000002699 waste material Substances 0.000 description 1
239000011701 zinc Substances 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1
GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Microbiology (AREA)
Mycology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Dermatology (AREA)
Zoology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Endocrinology (AREA)
Rheumatology (AREA)
Inorganic Chemistry (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Pain & Pain Management (AREA)
Medicinal Preparation (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

TW097146498A 2007-11-30 2008-11-28 Protein formulations and methods of making same TW200938221A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US499207P	2007-11-30	2007-11-30

Publications (1)

Publication Number	Publication Date
TW200938221A true TW200938221A (en)	2009-09-16

Family

ID=40718465

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
TW097146498A TW200938221A (en)	2007-11-30	2008-11-28	Protein formulations and methods of making same
TW104140979A TWI543768B (zh)	2007-11-30	2008-11-28	蛋白質調配物及製造其之方法
TW107115487A TWI661833B (zh)	2007-11-30	2008-11-28	蛋白質調配物及製造其之方法
TW102119838A TWI629064B (zh)	2007-11-30	2008-11-28	蛋白質調配物及製造其之方法

Family Applications After (3)

Application Number	Title	Priority Date	Filing Date
TW104140979A TWI543768B (zh)	2007-11-30	2008-11-28	蛋白質調配物及製造其之方法
TW107115487A TWI661833B (zh)	2007-11-30	2008-11-28	蛋白質調配物及製造其之方法
TW102119838A TWI629064B (zh)	2007-11-30	2008-11-28	蛋白質調配物及製造其之方法

Country Status (16)

Country	Link
US (1)	US8420081B2 (2)
EP (2)	EP2231175A4 (2)
JP (6)	JP5840364B2 (2)
KR (4)	KR20190045414A (2)
CN (3)	CN104740632A (2)
AU (1)	AU2008334099B2 (2)
BR (1)	BRPI0819714A8 (2)
CA (2)	CA2707483A1 (2)
IL (4)	IL206081A (2)
MX (1)	MX354100B (2)
NZ (4)	NZ602498A (2)
RU (2)	RU2473360C2 (2)
SG (2)	SG186607A1 (2)
TW (4)	TW200938221A (2)
WO (1)	WO2009073569A2 (2)
ZA (1)	ZA201205433B (2)

Families Citing this family (181)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6090382A (en)	1996-02-09	2000-07-18	Basf Aktiengesellschaft	Human antibodies that bind human TNFα
MX336813B (es) *	1996-02-09	2016-02-02	Abbvie Biotechnology Ltd	Anticuerpos humanos que ligan el tnfa humano.
US20160279239A1 (en)	2011-05-02	2016-09-29	Immunomedics, Inc.	Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
US8658773B2 (en)	2011-05-02	2014-02-25	Immunomedics, Inc.	Ultrafiltration concentration of allotype selected antibodies for small-volume administration
US20090280065A1 (en) *	2006-04-10	2009-11-12	Willian Mary K	Uses and Compositions for Treatment of Psoriasis
WO2004009776A2 (en) *	2002-07-19	2004-01-29	Abbott Biotechnology Ltd.	TREATMENT OF TNFα RELATED DISORDERS
US20040033228A1 (en)	2002-08-16	2004-02-19	Hans-Juergen Krause	Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en) *	2002-10-24	2014-02-28	Abbvie Biotechnology Ltd	Low dose methods for treating disorders in which tnf? activity is detrimental
TW201705980A (zh) *	2004-04-09	2017-02-16	艾伯維生物技術有限責任公司	用於治療ＴＮＦα相關失調症之多重可變劑量療法
GB0414054D0 (en)	2004-06-23	2004-07-28	Owen Mumford Ltd	Improvements relating to automatic injection devices
WO2006041970A2 (en) *	2004-10-08	2006-04-20	Abbott Biotechnology Ltd.	Treatment of respiratory syncytial virus (rsv) infection
US20160355591A1 (en)	2011-05-02	2016-12-08	Immunomedics, Inc.	Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
NZ595225A (en)	2005-05-16	2013-05-31	Abbott Biotech Ltd	Use of tnf inhibitor for treatment of erosive polyarthritis
BRPI0611901A2 (pt)	2005-06-14	2012-08-28	Amgen, Inc	composição, liofilizado, kit, e, processo para preparar uma composição
CN103336129A (zh) *	2005-11-01	2013-10-02	阿布维生物技术有限公司	使用生物标志物诊断强直性脊柱炎的方法和组合物
US9486408B2 (en)	2005-12-01	2016-11-08	University Of Massachusetts Lowell	Botulinum nanoemulsions
CN102887955A (zh)	2006-04-05	2013-01-23	艾博特生物技术有限公司	抗体纯化
WO2007120626A2 (en)	2006-04-10	2007-10-25	Abbott Biotechnology Ltd.	Uses and compositions for treatment of ankylosing spondylitis
US20090317399A1 (en) *	2006-04-10	2009-12-24	Pollack Paul F	Uses and compositions for treatment of CROHN'S disease
WO2008063213A2 (en)	2006-04-10	2008-05-29	Abbott Biotechnology Ltd.	Uses and compositions for treatment of psoriatic arthritis
US9399061B2 (en) *	2006-04-10	2016-07-26	Abbvie Biotechnology Ltd	Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
US9605064B2 (en) *	2006-04-10	2017-03-28	Abbvie Biotechnology Ltd	Methods and compositions for treatment of skin disorders
US20100021451A1 (en)	2006-06-08	2010-01-28	Wong Robert L	Uses and compositions for treatment of ankylosing spondylitis
US20080311043A1 (en) *	2006-06-08	2008-12-18	Hoffman Rebecca S	Uses and compositions for treatment of psoriatic arthritis
MX2008016335A (es)	2006-06-30	2009-01-21	Abbott Biotech Ltd	Dispositivo automatico de inyeccion.
US8911964B2 (en)	2006-09-13	2014-12-16	Abbvie Inc.	Fed-batch method of making human anti-TNF-alpha antibody
AU2007294731B2 (en)	2006-09-13	2014-04-17	Abbvie Inc.	Cell culture improvements
ES2442258T3 (es)	2006-10-27	2014-02-10	Abbvie Biotechnology Ltd	Anticuerpos cristalinos anti-hTNF alfa
AU2007234612B2 (en)	2006-12-14	2013-06-27	Johnson & Johnson Regenerative Therapeutics, Llc	Protein stabilization formulations
RU2476442C2 (ru)	2007-03-29	2013-02-27	Эббот Лэборетриз	Кристаллические антитела против il-12 человека
WO2008154543A2 (en)	2007-06-11	2008-12-18	Abbott Biotechnology Ltd.	Methods for treating juvenile idiopathic arthritis
US7678764B2 (en)	2007-06-29	2010-03-16	Johnson & Johnson Regenerative Therapeutics, Llc	Protein formulations for use at elevated temperatures
WO2009008595A1 (en)	2007-07-10	2009-01-15	Medy-Tox, Inc.	Pharmaceutical liquid composition of botulinum toxin with improved stability
JP2010533181A (ja) *	2007-07-13	2010-10-21	アボツト・バイオテクノロジー・リミテツド	ＴＮＦα阻害剤の肺投与のための方法及び組成物
JP5323832B2 (ja)	2007-08-07	2013-10-23	アドバンスト・テクノロジーズ・アンド・リジェネレイティブ・メディスン・エルエルシー	酸性水溶液中にｇｄｆ−５を含むタンパク質製剤
WO2009020654A1 (en)	2007-08-08	2009-02-12	Abbott Laboratories	Compositions and methods for crystallizing antibodies
US8420081B2 (en)	2007-11-30	2013-04-16	Abbvie, Inc.	Antibody formulations and methods of making same
US8883146B2 (en)	2007-11-30	2014-11-11	Abbvie Inc.	Protein formulations and methods of making same
US20090271164A1 (en) *	2008-01-03	2009-10-29	Peng Joanna Z	Predicting long-term efficacy of a compound in the treatment of psoriasis
CA2711984A1 (en)	2008-01-15	2009-07-23	Abbott Gmbh & Co. Kg	Powdered protein compositions and methods of making same
BRPI0911048A2 (pt)	2008-04-14	2015-12-29	Atrm Llc	formulações líquidas tamponadas de gdf-5
BRPI0920572A8 (pt)	2008-10-20	2015-10-27	Abbott Lab	Inativação viral durante a purificação dos anticorpos
NZ592095A (en)	2008-10-20	2013-01-25	Abbott Lab	Isolation and purification of il-12 and tnf-alpha antibodies using protein a affinity chromatography
WO2010127146A1 (en)	2009-04-29	2010-11-04	Abbott Biotechnology Ltd	Automatic injection device
US20130034534A1 (en) *	2009-09-29	2013-02-07	Philipp Kroneberg	Method for treatment of patients with cystic fibrosis
CN102574912B (zh)	2009-09-29	2014-12-24	弗·哈夫曼-拉罗切有限公司	缓冲溶质的过滤前调节
RU2582401C2 (ru)	2009-12-15	2016-04-27	Эббви Байотекнолоджи Лтд	Усовершенствованная пусковая кнопка для автоматического инъекционного устройства
JP2013518590A (ja)	2010-02-02	2013-05-23	アボツト・バイオテクノロジー・リミテツド	ＴＮＦ−α阻害剤を用いる処置に対する応答性を予測するための方法および組成物
EP2575884B1 (en)	2010-06-03	2018-07-18	AbbVie Biotechnology Ltd	Uses and compositions for treatment of hidradenitis suppurativa (hs)
JP6073783B2 (ja)	2010-06-25	2017-02-01	シャイアーヒューマンジェネティックセラピーズインコーポレイテッド	ヘパランｎ−スルファターゼのｃｎｓ送達のための方法および組成物
LT2588130T (lt)	2010-06-25	2016-12-12	Shire Human Genetic Therapies, Inc.	Terapinės priemonės pristatymas cns
PT3103469T (pt)	2010-06-25	2021-03-04	Shire Human Genetic Therapies	Administração de agentes terapêuticos no snc
KR20230159646A (ko)	2010-06-25	2023-11-21	샤이어 휴먼 지네틱 테라피즈 인크.	이듀로네이트-2-설파타제의 cns 전달을 위한 방법들 및 조성물들
HRP20191923T1 (hr)	2010-06-25	2020-01-10	Shire Human Genetic Therapies, Inc.	Postupci i sastavi za isporuku arilsulfataze a u cns
AR082319A1 (es) *	2010-07-22	2012-11-28	Biomarin Pharm Inc	Produccion de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos
MX2019000046A (es)	2010-11-04	2023-10-05	Boehringer Ingelheim Int	Anticuerpos anti-il-23.
US8821865B2 (en) *	2010-11-11	2014-09-02	Abbvie Biotechnology Ltd.	High concentration anti-TNFα antibody liquid formulations
CN106822883A (zh) *	2010-12-14	2017-06-13	葛兰素史密丝克莱恩生物有限公司	分枝杆菌抗原组合物
RU2727040C2 (ru)	2011-01-24	2020-07-17	Эббви Байотекнолоджи Лтд.	Автоматические инъекционные устройства, имеющие наформованные поверхности захвата
US9062106B2 (en)	2011-04-27	2015-06-23	Abbvie Inc.	Methods for controlling the galactosylation profile of recombinantly-expressed proteins
CN103930124B (zh) *	2011-07-01	2021-05-11	生物基因Ma公司	无精氨酸的tnfr：fc-融合多肽组合物及使用方法
GB201112429D0 (en) *	2011-07-19	2011-08-31	Glaxo Group Ltd	Antigen-binding proteins with increased FcRn binding
EP2758780A4 (en) *	2011-09-22	2015-09-16	Marv Entpr Llc	METHOD OF TREATING MULTIPLE SCLEROSIS
US10485869B2 (en)	2011-10-18	2019-11-26	Coherus Biosciences, Inc.	Etanercept formulations stabilized with meglumine
BR112014009146A8 (pt)	2011-10-18	2017-06-20	Coherus Biosciences Inc	formulações de etanercepte estabilizadas com aminoácidos
WO2013063277A1 (en)	2011-10-25	2013-05-02	Corning Incorporated	Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US20140377244A1 (en)	2011-12-23	2014-12-25	Shire Human Genetic Therapies, Inc.	Stable formulations for cns delivery of arylsulfatase a
WO2013096835A1 (en) *	2011-12-23	2013-06-27	Abbvie Inc.	Stable protein formulations
WO2013158273A1 (en)	2012-04-20	2013-10-24	Abbvie Inc.	Methods to modulate c-terminal lysine variant distribution
US9067990B2 (en)	2013-03-14	2015-06-30	Abbvie, Inc.	Protein purification using displacement chromatography
WO2013158279A1 (en)	2012-04-20	2013-10-24	Abbvie Inc.	Protein purification methods to reduce acidic species
PL3326649T3 (pl)	2012-05-03	2022-04-25	Boehringer Ingelheim International Gmbh	Przeciwciała anty-il-23p19
WO2013176754A1 (en)	2012-05-24	2013-11-28	Abbvie Inc.	Novel purification of antibodies using hydrophobic interaction chromatography
WO2013186230A1 (en) *	2012-06-12	2013-12-19	Boehringer Ingelheim International Gmbh	Pharmaceutical formulation for a therapeutic antibody
HK1209343A1 (en)	2012-07-09	2016-04-01	Coherus Biosciences, Inc.	Etanercept formulations exhibiting marked reduction in sub-visible particles
US8883979B2 (en)	2012-08-31	2014-11-11	Bayer Healthcare Llc	Anti-prolactin receptor antibody formulations
US9512214B2 (en)	2012-09-02	2016-12-06	Abbvie, Inc.	Methods to control protein heterogeneity
HK1211981A1 (en)	2012-09-02	2016-06-03	Abbvie Inc.	Methods to control protein heterogeneity
PE20150964A1 (es)	2012-09-07	2015-07-25	Coherus Biosciences Inc	Formulaciones acuosas estables de adalimumab
SI2895188T1 (en)	2012-09-11	2018-05-31	Coherus Biosciences, Inc.	CORRECTED QUALITY ETHANERCEPT WITH HIGH QUALITY AND EXCELLENT EXPERIENCE
US9844594B2 (en)	2012-12-18	2017-12-19	Merck Sharp & Dohme Corp.	Liquid formulations for an anti-TNF α antibody
HK1207960A1 (en)	2013-03-12	2016-02-19	Abbvie Inc.	Human antibodies that bind human tnf-alpha and methods of preparing the same
WO2014159579A1 (en)	2013-03-14	2014-10-02	Abbvie Inc.	MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
CA2899449A1 (en)	2013-03-14	2014-10-02	Abbvie Inc.	Low acidic species compositions and methods for producing the same using displacement chromatography
BR112015017307A2 (pt)	2013-03-14	2017-11-21	Abbvie Inc	composições de espécies com baixa acidez e métodos para produção e uso das mesmas
US9499614B2 (en)	2013-03-14	2016-11-22	Abbvie Inc.	Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US9017687B1 (en) *	2013-10-18	2015-04-28	Abbvie, Inc.	Low acidic species compositions and methods for producing and using the same using displacement chromatography
RS58351B1 (sr)	2013-03-15	2019-03-29	Shire Viropharma Inc	C1-inh kompozicije i postupci za prevenciju i lečenje poremećaja koji su povezani sa deficijencijom inhibitora c1 esteraze
US9700485B2 (en)	2013-04-24	2017-07-11	Corning Incorporated	Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9707154B2 (en)	2013-04-24	2017-07-18	Corning Incorporated	Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9717649B2 (en)	2013-04-24	2017-08-01	Corning Incorporated	Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9849066B2 (en)	2013-04-24	2017-12-26	Corning Incorporated	Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9707153B2 (en)	2013-04-24	2017-07-18	Corning Incorporated	Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9707155B2 (en)	2013-04-24	2017-07-18	Corning Incorporated	Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9839579B2 (en)	2013-04-24	2017-12-12	Corning Incorporated	Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9603775B2 (en)	2013-04-24	2017-03-28	Corning Incorporated	Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9713572B2 (en)	2013-04-24	2017-07-25	Corning Incorporated	Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9717648B2 (en) *	2013-04-24	2017-08-01	Corning Incorporated	Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9700486B2 (en)	2013-04-24	2017-07-11	Corning Incorporated	Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
IL312865B2 (en) *	2013-09-11	2025-06-01	Eagle Biologics Inc	Liquid protein formulations containing viscosity-lowering agents
US9598667B2 (en)	2013-10-04	2017-03-21	Abbvie Inc.	Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
EP3057616B1 (en)	2013-10-16	2020-03-11	Outlook Therapeutics, Inc.	Buffer formulations for enhanced antibody stability
US9181337B2 (en)	2013-10-18	2015-11-10	Abbvie, Inc.	Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en)	2013-10-18	2015-07-21	Abbvie, Inc.	Low acidic species compositions and methods for producing and using the same
US8946395B1 (en)	2013-10-18	2015-02-03	Abbvie Inc.	Purification of proteins using hydrophobic interaction chromatography
US20150139988A1 (en)	2013-11-15	2015-05-21	Abbvie, Inc.	Glycoengineered binding protein compositions
CN104707146B (zh) *	2013-12-16	2019-04-16	浙江海正药业股份有限公司	一种含有阿达木单抗的药物组合物
US10548951B2 (en)	2013-12-17	2020-02-04	Mhs Care-Innovation Llc	Compositions and methods for treating obesity and hyperphagia
RU2711478C2 (ru)	2013-12-17	2020-01-17	ЭмЭйчЭс КЕА-ИННОВЕЙШН ЭлЭлСи	Композиции и способы борьбы с накоплением жировой ткани
WO2015151115A1 (en)	2014-04-02	2015-10-08	Intas Pharmaceuticals Limited	Liquid pharmaceutical composition of adalimumab
ES2572919T3 (es)	2014-05-23	2016-06-03	Ares Trading S.A.	Composición farmacéutica líquida
PT2946765T (pt)	2014-05-23	2016-11-10	Ares Trading Sa	Composição farmacêutica líquida
EP2946767B1 (en) *	2014-05-23	2016-10-05	Ares Trading S.A.	Liquid pharmaceutical composition
WO2015196091A1 (en)	2014-06-20	2015-12-23	Reform Biologics, Llc	Viscosity-reducing excipient compounds for protein formulations
US10478498B2 (en)	2014-06-20	2019-11-19	Reform Biologics, Llc	Excipient compounds for biopolymer formulations
US11357857B2 (en) *	2014-06-20	2022-06-14	Comera Life Sciences, Inc.	Excipient compounds for protein processing
WO2016004197A1 (en)	2014-07-03	2016-01-07	Abbvie Inc.	Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using cobalt
WO2016007764A1 (en)	2014-07-09	2016-01-14	Abbvie Inc.	Methods for modulating the glycosylation profile of recombinant proteins using non-commonly used sugars
RU2696312C2 (ru)	2014-07-16	2019-08-01	Трансген Са	Онколитический вирус для экспрессии модуляторов иммунологических контрольных точек
EP3708679A1 (en)	2014-07-24	2020-09-16	Boehringer Ingelheim International GmbH	Biomarkers useful in the treatment of il-23a related diseases
EA202193002A2 (ru)	2014-09-03	2022-03-31	Бёрингер Ингельхайм Интернациональ Гмбх	Соединение, нацеленное на ил-23a и фно-альфа, и его применение
WO2016065181A1 (en)	2014-10-23	2016-04-28	Amgen Inc.	Reducing viscosity of pharmaceutical formulations
WO2016089946A1 (en) *	2014-12-02	2016-06-09	Biogen Ma Inc.	Methods and compositions for controlling antibody aggregation
WO2016118707A1 (en)	2015-01-21	2016-07-28	Oncobiologics, Inc.	Modulation of charge variants in a monoclonal antibody composition
MX2017009759A (es)	2015-01-28	2017-10-27	Pfizer	Formulacion de anticuerpo del anti-factor de crecimiento endotelial vascular (vegf) acuosa estable.
AU2016215535B2 (en)	2015-02-04	2021-09-16	Boehringer Ingelheim International Gmbh	Methods of treating inflammatory diseases
EP4523756A3 (en)	2015-02-13	2025-05-28	Transgene	Immunotherapeutic vaccine and antibody combination therapy
EP3078675A1 (en)	2015-04-10	2016-10-12	Ares Trading S.A.	Induction dosing regimen for the treatment of tnf alpha mediated disorders
CA3002373A1 (en) *	2015-10-23	2017-04-27	Reform Biologics, Llc	Excipient compounds for biopolymer formulations
US11229702B1 (en)	2015-10-28	2022-01-25	Coherus Biosciences, Inc.	High concentration formulations of adalimumab
CN109563161A (zh)	2016-02-03	2019-04-02	安口生物公司	用于提高抗体稳定性的缓冲制剂
GB201603280D0 (en)	2016-02-24	2016-04-13	Ferring Bv	Stable liquid gonadotropin formulation
EP3439701A4 (en)	2016-04-08	2019-12-11	180 Therapeutics LP	METHOD FOR THE TREATMENT OF DUPUYTRIAL DISEASE IN EARLY STAGE
US11071782B2 (en)	2016-04-20	2021-07-27	Coherus Biosciences, Inc.	Method of filling a container with no headspace
WO2018033482A1 (en) *	2016-08-17	2018-02-22	Boehringer Ingelheim International Gmbh	Process for the preparation of highly concentrated liquid formulations containing biomolecules
CN107773755B (zh) *	2016-08-31	2021-06-22	上海津曼特生物科技有限公司	抗表皮生长因子受体单克隆抗体的注射液制剂
KR102480965B1 (ko)	2016-09-13	2022-12-26	알레간 인코포레이티드	안정화된 비단백질 클로스트리듐 독소 조성물
CN110177805B (zh)	2016-10-19	2024-04-02	英温拉公司	抗体构建体
PT3528787T (pt)	2016-10-21	2026-03-11	Amgen Inc	Formulações farmacêuticas e métodos para produzir as mesmas
MX2019005833A (es)	2016-11-21	2019-10-30	Eirion Therapeutics Inc	Administracion transdermica de agentes grandes.
EP3541413A2 (en)	2016-11-21	2019-09-25	Polpharma Biologics S.A.	Aqueous pharmaceutical formulations
WO2018119142A1 (en)	2016-12-21	2018-06-28	Amgen Inc.	Anti-tnf alpha antibody formulations
AU2017383142A1 (en)	2016-12-22	2019-07-04	Università Degli Studi Magna Graecia Catanzaro	A monoclonal antibody targeting a unique sialoglycosilated cancer-associated epitope of CD43
AU2017386888B2 (en)	2016-12-28	2024-08-08	Jcr Pharmaceuticals Co., Ltd.	Lyophilized preparation
RU2665966C2 (ru) *	2016-12-30	2018-09-05	Закрытое Акционерное Общество "Биокад"	Водная фармацевтическая композиция рекомбинантного моноклонального антитела к ФНОα
JP6172880B1 (ja) *	2017-02-01	2017-08-02	協和発酵キリン株式会社	ダルベポエチンを含む液体医薬組成物
JP7377596B2 (ja)	2017-02-22	2023-11-10	アムジエン・インコーポレーテツド	低粘度、高濃度エボロクマブ製剤及びそれらの製造方法
US10799597B2 (en)	2017-04-03	2020-10-13	Immunomedics, Inc.	Subcutaneous administration of antibody-drug conjugates for cancer therapy
CN110769848A (zh) *	2017-05-16	2020-02-07	瑞士奥克特珐玛公司	C1-酯酶抑制剂制剂
JP7820910B2 (ja)	2017-09-20	2026-02-26	アルヴォテックエイチエフ	アダリムマブ用医薬製剤
EP3459527B1 (en) *	2017-09-20	2022-11-23	Tillotts Pharma Ag	Method for preparing a solid dosage form comprising antibodies by wet granulation, extrusion and spheronization
RU2020121415A (ru) *	2017-11-30	2021-12-30	Био-Тера Солюшнз, Лтд.	Жидкий препарат гуманизированного антитела для лечения заболеваний, опосредованных ил-6
GB201721846D0 (en) *	2017-12-22	2018-02-07	Arecor Ltd	Novel composition
WO2019147824A1 (en)	2018-01-26	2019-08-01	Progenity, Inc.	Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
MX2020010724A (es) *	2018-04-12	2020-11-06	Amgen Inc	Metodos para preparar composiciones proteicas estables.
CN120795120A (zh)	2018-06-05	2025-10-17	伦敦大学国王学院	向胃肠系统递送酬载的btnl3/8导引构建体
WO2019246312A1 (en)	2018-06-20	2019-12-26	Progenity, Inc.	Treatment of a disease of the gastrointestinal tract with an immunomodulator
US20230033021A1 (en)	2018-06-20	2023-02-02	Progenity, Inc.	Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
US20210363233A1 (en)	2018-06-20	2021-11-25	Progenity, Inc.	Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor
WO2019246317A1 (en)	2018-06-20	2019-12-26	Progenity, Inc.	Treatment of a disease or condition in a tissue originating from the endoderm
WO2019246273A1 (en)	2018-06-20	2019-12-26	Progenity, Inc.	Treatment of a disease of the gastrointestinal tract with a jak or other kinase inhibitor
US20230312700A1 (en)	2018-06-20	2023-10-05	Progenity, Inc.	Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
MY195550A (en)	2018-10-29	2023-01-31	Hoffmann La Roche	Antibody Formulation
CN111228225B (zh) *	2018-11-28	2022-08-26	鲁南制药集团股份有限公司	一种重组人肿瘤坏死因子受体-Fc融合蛋白冻干制剂
US20220080023A1 (en)	2018-12-21	2022-03-17	Arecor Limited	Novel composition
CN120241997A (zh)	2019-02-18	2025-07-04	伊莱利利公司	治疗性抗体制剂
WO2020232247A1 (en)	2019-05-14	2020-11-19	Provention Bio, Inc.	Methods and compositions for preventing type 1 diabetes
AU2020279395B2 (en)	2019-05-22	2025-08-28	Biovie Inc.	Formulations of terlipressin
US11684655B2 (en)	2019-05-31	2023-06-27	Spectrum Pharmaceuticals, Inc.	Methods of treating neutorpenia using G-CSF protein complex
US11267858B2 (en)	2019-05-31	2022-03-08	Spectrum Pharmaceuticals, Inc.	Methods of treatment using G-CSF protein complex
GB201911461D0 (en)	2019-08-09	2019-09-25	Arecor Ltd	Novel composition
CN110467273B (zh) *	2019-08-27	2021-08-24	暨南大学	一种垃圾渗滤液浓缩液的微生物毒性及可生化性评价方法及其应用
TW202535466A (zh)	2019-09-09	2025-09-16	德商百靈佳殷格翰國際股份有限公司	抗-il-23p19抗體調配物
IL298999A (en)	2020-06-11	2023-02-01	Provention Bio Inc	Methods and compositions for the prevention of type 1 diabetes
KR102414997B1 (ko) *	2020-09-29	2022-06-29	주식회사 엘지생활건강	안정성이 개선된 재조합 보툴리눔 독소 경쇄 단백질 조성물
KR102375269B1 (ko) *	2021-01-27	2022-03-17	한미약품 주식회사	단백질 액상 제제 및 이의 제조방법
US20240166718A1 (en)	2021-02-17	2024-05-23	Arecor Limited	Aqueous composition of an engineered protein construct comprising an fc domain
JP2024520444A (ja)	2021-05-24	2024-05-24	プロヴェンション・バイオ・インコーポレイテッド	１型糖尿病を治療するための方法
JP2024527538A (ja) *	2021-07-01	2024-07-25	アップカラインコーポレイテッド	生物活性剤の超濃縮製剤
AU2023300419A1 (en)	2022-07-01	2025-01-02	Transgene	Fusion protein comprising a surfactant-protein-d and a member of the tnfsf
CH720224B1 (de) *	2023-08-18	2024-05-31	Csl Behring Ag	Verfahren zur Sterilfiltration albuminhaltiger wässriger Lösungen

Family Cites Families (148)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2413974A1 (fr)	1978-01-06	1979-08-03	David Bernard	Sechoir pour feuilles imprimees par serigraphie
US5702699A (en) *	1982-09-23	1997-12-30	Cetus Corporation	Process for the recovery of lipophilic proteins
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4597966A (en) *	1985-01-09	1986-07-01	Ortho Diagnostic Systems, Inc.	Histidine stabilized immunoglobulin and method of preparation
US4676980A (en)	1985-09-23	1987-06-30	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Target specific cross-linked heteroantibodies
US4877608A (en) *	1987-11-09	1989-10-31	Rorer Pharmaceutical Corporation	Pharmaceutical plasma protein formulations in low ionic strength media
ES2096590T3 (es)	1989-06-29	1997-03-16	Medarex Inc	Reactivos biespecificos para la terapia del sida.
JP3443119B2 (ja)	1989-08-07	2003-09-02	ペプテックリミテッド	腫瘍壊死因子結合リガンド
GB9017002D0 (en) *	1990-08-02	1990-09-19	Health Lab Service Board	Improved method for the purification of erwina l-asparaginase
US5469750A (en)	1991-03-05	1995-11-28	Aradigm Corporation	Method and apparatus for sensing flow in two directions and automatic calibration thereof
US6277969B1 (en) *	1991-03-18	2001-08-21	New York University	Anti-TNF antibodies and peptides of human tumor necrosis factor
US20060246073A1 (en) *	1991-03-18	2006-11-02	Knight David M	Anti-TNF antibodies and peptides of human tumor necrosis factor
WO1992020373A1 (en)	1991-05-14	1992-11-26	Repligen Corporation	Heteroconjugate antibodies for treatment of hiv infection
WO1993008829A1 (en)	1991-11-04	1993-05-13	The Regents Of The University Of California	Compositions that mediate killing of hiv-infected cells
CA2140280A1 (en)	1992-08-17	1994-03-03	Avi J. Ashkenazi	Bispecific immunoadhesins
US5694919A (en)	1993-01-29	1997-12-09	Aradigm Corporation	Lockout device for controlled release of drug from patient-activated dispenser
US5507277A (en)	1993-01-29	1996-04-16	Aradigm Corporation	Lockout device for controlled release of drug from patient-activateddispenser
US5888477A (en)	1993-01-29	1999-03-30	Aradigm Corporation	Use of monomeric insulin as a means for improving the bioavailability of inhaled insulin
DK0682710T3 (da)	1993-02-10	2004-03-01	Unilever Nv	Isolationsmetode, ved hvilken der anvendes immobiliserede proteiner med specifikke kapaciteter
US5922545A (en)	1993-10-29	1999-07-13	Affymax Technologies N.V.	In vitro peptide and antibody display libraries
DE4344824C1 (de) *	1993-12-28	1995-08-31	Immuno Ag	Hochkonzentriertes Immunglobulin-Präparat und Verfahren zu seiner Herstellung
US5509404A (en)	1994-07-11	1996-04-23	Aradigm Corporation	Intrapulmonary drug delivery within therapeutically relevant inspiratory flow/volume values
US5522385A (en)	1994-09-27	1996-06-04	Aradigm Corporation	Dynamic particle size control for aerosolized drug delivery
US6090382A (en)	1996-02-09	2000-07-18	Basf Aktiengesellschaft	Human antibodies that bind human TNFα
MX336813B (es)	1996-02-09	2016-02-02	Abbvie Biotechnology Ltd	Anticuerpos humanos que ligan el tnfa humano.
US6300065B1 (en)	1996-05-31	2001-10-09	Board Of Trustees Of The University Of Illinois	Yeast cell surface display of proteins and uses thereof
US6696251B1 (en)	1996-05-31	2004-02-24	Board Of Trustees Of The University Of Illinois	Yeast cell surface display of proteins and uses thereof
US6699658B1 (en)	1996-05-31	2004-03-02	Board Of Trustees Of The University Of Illinois	Yeast cell surface display of proteins and uses thereof
US6261804B1 (en)	1997-01-21	2001-07-17	The General Hospital Corporation	Selection of proteins using RNA-protein fusions
ATE332368T1 (de)	1997-01-21	2006-07-15	Gen Hospital Corp	Selektion von proteinen mittels rns-protein fusionen
GB9705810D0 (en) *	1997-03-20	1997-05-07	Common Services Agency	Intravenous immune globulin
EP0975748B1 (en)	1997-04-23	2006-03-29	Universität Zürich	Methods for identifying nucleic acid molecules encoding (poly)peptides that interact with target molecules
CZ298429B6 (cs) *	1997-04-28	2007-10-03	Eli Lilly And Company	Stabilní lyofilizovaný prostredek
US6171586B1 (en) *	1997-06-13	2001-01-09	Genentech, Inc.	Antibody formulation
US5886154A (en) *	1997-06-20	1999-03-23	Lebing; Wytold R.	Chromatographic method for high yield purification and viral inactivation of antibodies
JPH1129294A (ja) *	1997-07-09	1999-02-02	Tochigi Fuji Ind Co Ltd	ウインチ
US5855564A (en)	1997-08-20	1999-01-05	Aradigm Corporation	Aerosol extrusion mechanism
CA2323638A1 (en)	1998-04-03	1999-10-14	Phylos, Inc.	Addressable protein arrays
DK2270044T3 (en) *	1998-06-09	2015-01-26	Csl Behring Ag	Liquid immunoglobulin G (IgG) product
US6846655B1 (en)	1998-06-29	2005-01-25	Phylos, Inc.	Methods for generating highly diverse libraries
JP2002522091A (ja)	1998-08-17	2002-07-23	フィロスインク．	３’非翻訳領域を欠損する核酸を生成して細胞ｒｎａ蛋白質融合体形成を最適化する方法
JP4278872B2 (ja)	1998-08-17	2009-06-17	フィロスインク．	蛋白質・核酸融合分子ライブラリーを用いた化合物・蛋白質相互作用の同定
NZ511699A (en)	1998-12-02	2003-02-28	Phylos Inc	DNA-protein fusions and uses thereof
DK1144616T4 (da)	1999-01-19	2009-03-30	Unilever Nv	Fremgangsmåde til fremstilling af antistoffragmenter
US6914128B1 (en)	1999-03-25	2005-07-05	Abbott Gmbh & Co. Kg	Human antibodies that bind human IL-12 and methods for producing
CA2371427A1 (en)	1999-04-28	2000-11-09	Yamanouchi Pharmaceutical Co., Ltd.	Parenteral pharmaceutical composition containing humanized monoclonal antibody fragment and stabilizing method thereof
US6623926B1 (en)	1999-06-01	2003-09-23	Phylos, Inc.	Methods for producing 5′-nucleic acid-protein conjugates
AU778194B2 (en)	1999-07-12	2004-11-18	Bristol-Myers Squibb Company	C-terminal protein tagging
DK1196637T3 (da)	1999-07-27	2007-07-30	Adnexus Therapeutics Inc	Peptidacceptor-ligeringsmetoder
US6436665B1 (en)	1999-08-27	2002-08-20	Phylos, Inc	Methods for encoding and sorting in vitro translated proteins
US7022479B2 (en)	2000-01-24	2006-04-04	Compound Therapeutics, Inc.	Sensitive, multiplexed diagnostic assays for protein analysis
DE60118527D1 (de)	2000-01-24	2006-05-18	Compound Therapeutics Inc	Sensible und multiplexe diagnostische tests zur proteinanalyse
DE10013093B4 (de)	2000-03-17	2005-12-22	Inamed Gmbh	Vorrichtung zur kontrollierten Inhalation therapeutischer Aerosole
JP5490972B2 (ja) *	2000-08-04	2014-05-14	中外製薬株式会社	タンパク質注射製剤
UA81743C2 (uk) *	2000-08-07	2008-02-11	Центокор, Инк.	МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
JP5485489B2 (ja) *	2000-08-11	2014-05-07	中外製薬株式会社	抗体含有安定化製剤
US6693173B2 (en) *	2000-12-26	2004-02-17	Alpha Therapeutic Corporation	Method to remove citrate and aluminum from proteins
DE10123749A1 (de)	2001-05-16	2002-12-12	Inamed Gmbh	Vorrichtung zum Verabreichen von Aerosolen
US7458374B2 (en)	2002-05-13	2008-12-02	Alexza Pharmaceuticals, Inc.	Method and apparatus for vaporizing a compound
US20030012786A1 (en)	2001-05-25	2003-01-16	Teoh Leah S.	Use of anti-TNF antibodies as drugs in treating septic disorders of anemic patients
GB0113179D0 (en) *	2001-05-31	2001-07-25	Novartis Ag	Organic compounds
CA2817619A1 (en)	2001-06-08	2002-12-08	Abbott Laboratories (Bermuda) Ltd.	Methods of administering anti-tnf.alpha. antibodies
AU2002310502A1 (en)	2001-06-21	2003-01-08	Phylos, Inc.	In vitro protein interaction detection systems
AU2002365404A1 (en)	2001-11-27	2003-06-10	Compound Therapeutics, Inc.	Solid-phase immobilization of proteins and peptides
US20030143603A1 (en) *	2001-11-30	2003-07-31	Jill Giles-Komar	Anti-TNF antibodies, compositions, methods and uses
GB0202633D0 (en) *	2002-02-05	2002-03-20	Delta Biotechnology Ltd	Stabilization of protein preparations
CN101721362B (zh) *	2002-02-14	2018-07-03	中外制药株式会社	包含抗体的溶液制剂
US20030161828A1 (en)	2002-02-19	2003-08-28	Abbott Gmbh & Co. Kg	Use of TNF antagonists as drugs for the treatment of patients with an inflammatory reaction and without suffering from total organ failure
SI1478394T1 (sl) *	2002-02-27	2008-12-31	Immunex Corp	STABILIZIRAN TNFR-Fc SESTAVEK Z ARGININOM
US20040105889A1 (en) *	2002-12-03	2004-06-03	Elan Pharma International Limited	Low viscosity liquid dosage forms
US20040009172A1 (en)	2002-04-26	2004-01-15	Steven Fischkoff	Use of anti-TNFalpha antibodies and another drug
US20030206898A1 (en)	2002-04-26	2003-11-06	Steven Fischkoff	Use of anti-TNFalpha antibodies and another drug
CN1671741A (zh) *	2002-06-21	2005-09-21	拜奥根Idec公司	浓缩抗体的缓冲剂制剂及其使用方法
WO2004004798A2 (en) *	2002-07-03	2004-01-15	The Brigham And Women's Hospital, Inc.	Central airway administration for systemic delivery of therapeutics
US20090280065A1 (en)	2006-04-10	2009-11-12	Willian Mary K	Uses and Compositions for Treatment of Psoriasis
WO2004009776A2 (en)	2002-07-19	2004-01-29	Abbott Biotechnology Ltd.	TREATMENT OF TNFα RELATED DISORDERS
US20040033228A1 (en) *	2002-08-16	2004-02-19	Hans-Juergen Krause	Formulation of human antibodies for treating TNF-alpha associated disorders
EP3225625A1 (en) *	2002-09-11	2017-10-04	Chugai Seiyaku Kabushiki Kaisha	Protein purification method
MY150740A (en)	2002-10-24	2014-02-28	Abbvie Biotechnology Ltd	Low dose methods for treating disorders in which tnf? activity is detrimental
JP4500683B2 (ja) *	2002-11-01	2010-07-14	バイエル・ヘルスケア・エルエルシー	巨大分子濃縮方法
US20040086532A1 (en) *	2002-11-05	2004-05-06	Allergan, Inc.,	Botulinum toxin formulations for oral administration
KR101235507B1 (ko) *	2003-02-28	2013-02-20	추가이 세이야쿠 가부시키가이샤	단백질을 함유하는 안정화 제제
JP4980048B2 (ja) *	2003-02-28	2012-07-18	アレストレーディングソシエテアノニム	腫瘍壊死因子結合タンパク質の液体製剤
MXPA05010555A (es) *	2003-04-04	2006-03-09	Genentech Inc	Formulaciones de proteina y anticuerpo de alta concentracion.
FR2853551B1 (fr) *	2003-04-09	2006-08-04	Lab Francais Du Fractionnement	Formulation stabilisante pour compositions d'immunoglobulines g sous forme liquide et sous forme lyophilisee
US7456147B2 (en) *	2003-05-14	2008-11-25	Dow Corning, Corporation	Controlled release of active agents utilizing repeat sequence protein polymers
RU2364609C2 (ru) *	2003-05-23	2009-08-20	Ново Нордиск Хелт Кэр Аг	Стабилизация белка в растворе
DE602004017726D1 (de) *	2003-06-30	2008-12-24	Domantis Ltd	Pegylierte Single-domain-antikörper (dAb)
HUE026793T2 (en) *	2003-10-01	2016-07-28	Kyowa Hakko Kirin Co Ltd	A method for stabilizing an antibody and a stabilized solution-type antibody preparation
EP1532983A1 (en) *	2003-11-18	2005-05-25	ZLB Bioplasma AG	Immunoglobulin preparations having increased stability
EP1712240B1 (en) *	2003-12-25	2015-09-09	Kyowa Hakko Kirin Co., Ltd.	Stable water-based medicinal preparation containing antibody
WO2005072772A1 (en)	2004-01-30	2005-08-11	Suomen Punainen Risti Veripalvelu	Pharmaceutical compositions
RU2390353C2 (ru) *	2004-02-12	2010-05-27	Мерк Патент Гмбх	Высококонцентрированные жидкие композиции анти-egfr антител
CA2561845C (en)	2004-04-02	2014-03-25	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention	Aerosol delivery systems and methods
TW201705980A (zh)	2004-04-09	2017-02-16	艾伯維生物技術有限責任公司	用於治療ＴＮＦα相關失調症之多重可變劑量療法
AU2005249360B2 (en) *	2004-04-12	2011-07-21	Medimmune, Llc	Anti-IL-9 antibody formulations and uses thereof
MXPA06012992A (es) *	2004-05-12	2007-02-12	Baxter Int	Microesferas que comprenden proteina y que muestran inyectabilidad en altas concentraciones de este agente.
TW200621282A (en) *	2004-08-13	2006-07-01	Wyeth Corp	Stabilizing formulations
WO2006022599A1 (en) *	2004-08-27	2006-03-02	Marian Metke	Production method for exfoliated graphite, equipment for its production, exfoliated graphite and means of its use
US20060051347A1 (en) *	2004-09-09	2006-03-09	Winter Charles M	Process for concentration of antibodies and therapeutic products thereof
WO2006041970A2 (en)	2004-10-08	2006-04-20	Abbott Biotechnology Ltd.	Treatment of respiratory syncytial virus (rsv) infection
WO2007011390A2 (en) *	2004-10-09	2007-01-25	Government Of The United States As Represented By The Secretary Of The Army	Large-scale production of human serum butyrylcholinesterase as a bioscavenger
WO2006064373A2 (en) *	2004-12-16	2006-06-22	Genzyme Polyclonals S.A.S.	Methods of purifying immunologlobulins
PA8661401A1 (es) *	2005-01-28	2006-09-08	Wyeth Corp	Formulaciones del liquido polipeptido estabilizado
CA2606270A1 (en) *	2005-04-19	2006-10-26	Massachusetts Institute Of Technology	Amphiphilic polymers and methods of use thereof
NZ595225A (en)	2005-05-16	2013-05-31	Abbott Biotech Ltd	Use of tnf inhibitor for treatment of erosive polyarthritis
BRPI0611901A2 (pt) *	2005-06-14	2012-08-28	Amgen, Inc	composição, liofilizado, kit, e, processo para preparar uma composição
US20060286108A1 (en) *	2005-06-16	2006-12-21	Bell Katherine A	Topical compositions for the treatment of chronic wounds
DE602006020568D1 (de) *	2005-07-02	2011-04-21	Arecor Ltd	Stabile wässrige systeme mit proteinen
WO2007016562A2 (en) *	2005-07-29	2007-02-08	Amgen Inc.	Formulations that inhibit protein aggregation
US20070041905A1 (en)	2005-08-19	2007-02-22	Hoffman Rebecca S	Method of treating depression using a TNF-alpha antibody
RU2422035C2 (ru) *	2005-09-21	2011-06-27	Баркон Ньютрасайнс (Мб) Корп.	Способ получения белкового изолята канолы, включающий изоэлектрическое осаждение
CN103336129A (zh)	2005-11-01	2013-10-02	阿布维生物技术有限公司	使用生物标志物诊断强直性脊柱炎的方法和组合物
US8337814B2 (en) *	2005-12-15	2012-12-25	Topical Sinus Therapeutics, Inc.	Treatment of active infections, sinusitis, rhinitis, and related neurological disorders and related compositions
BRPI0620316A2 (pt) *	2005-12-21	2011-11-08	Wyeth Corp	formulações de proteìnas com viscosidades reduzida e seus usos
US20070202051A1 (en) *	2006-02-10	2007-08-30	Pari Gmbh	Aerosols for sinunasal drug delivery
CN102887955A (zh)	2006-04-05	2013-01-23	艾博特生物技术有限公司	抗体纯化
US20090317399A1 (en)	2006-04-10	2009-12-24	Pollack Paul F	Uses and compositions for treatment of CROHN'S disease
US9605064B2 (en) *	2006-04-10	2017-03-28	Abbvie Biotechnology Ltd	Methods and compositions for treatment of skin disorders
WO2007120626A2 (en)	2006-04-10	2007-10-25	Abbott Biotechnology Ltd.	Uses and compositions for treatment of ankylosing spondylitis
US20080118496A1 (en)	2006-04-10	2008-05-22	Medich John R	Uses and compositions for treatment of juvenile rheumatoid arthritis
US9399061B2 (en)	2006-04-10	2016-07-26	Abbvie Biotechnology Ltd	Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
WO2008063213A2 (en)	2006-04-10	2008-05-29	Abbott Biotechnology Ltd.	Uses and compositions for treatment of psoriatic arthritis
US20080131374A1 (en)	2006-04-19	2008-06-05	Medich John R	Uses and compositions for treatment of rheumatoid arthritis
US20080311043A1 (en)	2006-06-08	2008-12-18	Hoffman Rebecca S	Uses and compositions for treatment of psoriatic arthritis
US20100021451A1 (en)	2006-06-08	2010-01-28	Wong Robert L	Uses and compositions for treatment of ankylosing spondylitis
MX2008016335A (es) *	2006-06-30	2009-01-21	Abbott Biotech Ltd	Dispositivo automatico de inyeccion.
AU2007294731B2 (en)	2006-09-13	2014-04-17	Abbvie Inc.	Cell culture improvements
US20100129379A1 (en) *	2006-09-25	2010-05-27	John Carpenter	Stabilized antibody formulations and uses thereof
ES2442258T3 (es)	2006-10-27	2014-02-10	Abbvie Biotechnology Ltd	Anticuerpos cristalinos anti-hTNF alfa
BRPI0720125A2 (pt) *	2006-12-06	2014-01-28	Wyeth Corp	Método para armazenar uma formulação líquida; método para a preparação de uma formulação líquida; composição; e método para inibir a agregação induzida por manitol de uma proteína em uma formulação líquida.
CA2675602A1 (en) *	2007-02-16	2008-08-21	Wyeth	Protein formulations containing sorbitol
WO2008150491A2 (en)	2007-05-31	2008-12-11	Abbott Laboratories	BIOMARKERS PREDICTIVE OF THE RESPONSIVENESS TO TNFα INHIBITORS IN AUTOIMMUNE DISORDERS
EP2152318A4 (en)	2007-06-01	2011-12-07	Abbott Biotech Ltd	COMPOSITIONS AND USES FOR THE TREATMENT OF PSORIASIS AND CROHN'S DISEASE
WO2008154543A2 (en)	2007-06-11	2008-12-18	Abbott Biotechnology Ltd.	Methods for treating juvenile idiopathic arthritis
JP2010533181A (ja)	2007-07-13	2010-10-21	アボツト・バイオテクノロジー・リミテツド	ＴＮＦα阻害剤の肺投与のための方法及び組成物
JP5399389B2 (ja) *	2007-08-06	2014-01-29	テレフオンアクチーボラゲットエルエムエリクソン（パブル）	Ｌｔｅシステムにおけるｏｆｄｍａアップリンクの干渉による影響の回復
WO2009020654A1 (en)	2007-08-08	2009-02-12	Abbott Laboratories	Compositions and methods for crystallizing antibodies
US8420081B2 (en)	2007-11-30	2013-04-16	Abbvie, Inc.	Antibody formulations and methods of making same
US20090271164A1 (en)	2008-01-03	2009-10-29	Peng Joanna Z	Predicting long-term efficacy of a compound in the treatment of psoriasis
CA2711984A1 (en)	2008-01-15	2009-07-23	Abbott Gmbh & Co. Kg	Powdered protein compositions and methods of making same
TWI478937B (zh)	2008-01-15	2015-04-01	Abbvie Inc	改良之哺乳動物表現載體及其用途
JP2011517672A (ja)	2008-03-24	2011-06-16	アボツト・バイオテクノロジー・リミテツド	骨損失を治療するための方法及び組成物
JP2012511531A (ja) *	2008-12-09	2012-05-24	エフ．ホフマン−ラロシュアーゲー	賦形剤不含抗体溶液を得るための方法
WO2010127146A1 (en) *	2009-04-29	2010-11-04	Abbott Biotechnology Ltd	Automatic injection device
US20100278822A1 (en) *	2009-05-04	2010-11-04	Abbott Biotechnology, Ltd.	Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
JP2013518590A (ja) *	2010-02-02	2013-05-23	アボツト・バイオテクノロジー・リミテツド	ＴＮＦ−α阻害剤を用いる処置に対する応答性を予測するための方法および組成物
EP2575884B1 (en) *	2010-06-03	2018-07-18	AbbVie Biotechnology Ltd	Uses and compositions for treatment of hidradenitis suppurativa (hs)

2008
- 2008-11-28 US US12/325,049 patent/US8420081B2/en active Active
- 2008-11-28 CN CN201510111453.6A patent/CN104740632A/zh active Pending
- 2008-11-28 WO PCT/US2008/085066 patent/WO2009073569A2/en not_active Ceased
- 2008-11-28 TW TW097146498A patent/TW200938221A/zh unknown
- 2008-11-28 NZ NZ602498A patent/NZ602498A/en unknown
- 2008-11-28 EP EP08857510.5A patent/EP2231175A4/en not_active Withdrawn
- 2008-11-28 CN CN2008801254027A patent/CN101969971A/zh active Pending
- 2008-11-28 TW TW104140979A patent/TWI543768B/zh not_active IP Right Cessation
- 2008-11-28 TW TW107115487A patent/TWI661833B/zh not_active IP Right Cessation
- 2008-11-28 CA CA2707483A patent/CA2707483A1/en not_active Abandoned
- 2008-11-28 BR BRPI0819714A patent/BRPI0819714A8/pt active Search and Examination
- 2008-11-28 MX MX2010005919A patent/MX354100B/es active IP Right Grant
- 2008-11-28 CN CN201510111763.8A patent/CN104645329A/zh active Pending
- 2008-11-28 SG SG2012087896A patent/SG186607A1/en unknown
- 2008-11-28 KR KR1020197011765A patent/KR20190045414A/ko not_active Ceased
- 2008-11-28 KR KR1020217012131A patent/KR20210049186A/ko not_active Ceased
- 2008-11-28 SG SG10201604258YA patent/SG10201604258YA/en unknown
- 2008-11-28 NZ NZ709704A patent/NZ709704A/en unknown
- 2008-11-28 NZ NZ622583A patent/NZ622583A/en unknown
- 2008-11-28 JP JP2010536208A patent/JP5840364B2/ja active Active
- 2008-11-28 KR KR1020107014593A patent/KR101868778B1/ko active Active
- 2008-11-28 KR KR1020157017584A patent/KR20150080038A/ko not_active Ceased
- 2008-11-28 AU AU2008334099A patent/AU2008334099B2/en active Active
- 2008-11-28 RU RU2010126658/15A patent/RU2473360C2/ru active
- 2008-11-28 CA CA2904458A patent/CA2904458C/en active Active
- 2008-11-28 TW TW102119838A patent/TWI629064B/zh not_active IP Right Cessation
- 2008-11-28 NZ NZ585702A patent/NZ585702A/xx not_active Application Discontinuation
- 2008-11-28 EP EP16200363.6A patent/EP3189831A1/en not_active Withdrawn
2010
- 2010-05-30 IL IL206081A patent/IL206081A/en active IP Right Grant
2012
- 2012-07-19 ZA ZA2012/05433A patent/ZA201205433B/en unknown
- 2012-11-06 RU RU2012147070A patent/RU2659431C2/ru active
2013
- 2013-12-09 IL IL229886A patent/IL229886B/en active IP Right Grant
2014
- 2014-04-01 JP JP2014075367A patent/JP2014159437A/ja active Pending
2015
- 2015-06-03 JP JP2015112856A patent/JP6752500B2/ja active Active
2016
- 2016-05-30 JP JP2016107020A patent/JP2016185971A/ja active Pending
2017
- 2017-12-21 IL IL256465A patent/IL256465B/en active IP Right Grant
2018
- 2018-01-23 JP JP2018008763A patent/JP2018080202A/ja active Pending
- 2018-10-08 IL IL262205A patent/IL262205A/en unknown
2020
- 2020-06-23 JP JP2020107507A patent/JP2020183387A/ja active Pending

Also Published As

Publication number	Publication date
SG186607A1 (en)	2013-01-30
CA2904458C (en)	2017-07-25
US20090291062A1 (en)	2009-11-26
MX2010005919A (es)	2010-08-10
KR20210049186A (ko)	2021-05-04
IL256465B (en)	2020-01-30
NZ602498A (en)	2014-08-29
JP2016185971A (ja)	2016-10-27
AU2008334099A1 (en)	2009-06-11
TW201841648A (zh)	2018-12-01
JP2015212267A (ja)	2015-11-26
JP2018080202A (ja)	2018-05-24
KR20190045414A (ko)	2019-05-02
TW201609142A (zh)	2016-03-16
NZ585702A (en)	2013-08-30
CN101969971A (zh)	2011-02-09
IL262205A (en)	2018-11-29
ZA201205433B (en)	2013-06-26
KR20100103543A (ko)	2010-09-27
TWI543768B (zh)	2016-08-01
MX354100B (es)	2018-02-13
TWI661833B (zh)	2019-06-11
NZ709704A (en)	2017-03-31
KR101868778B1 (ko)	2018-06-21
JP2020183387A (ja)	2020-11-12
KR20150080038A (ko)	2015-07-08
CN104740632A (zh)	2015-07-01
TW201336511A (zh)	2013-09-16
EP3189831A1 (en)	2017-07-12
AU2008334099B2 (en)	2014-07-24
CA2904458A1 (en)	2009-06-11
JP6752500B2 (ja)	2020-09-09
EP2231175A4 (en)	2014-07-16
RU2473360C2 (ru)	2013-01-27
TWI629064B (zh)	2018-07-11
RU2012147070A (ru)	2014-05-20
RU2659431C2 (ru)	2018-07-02
IL256465A (en)	2018-02-28
RU2010126658A (ru)	2012-01-10
NZ622583A (en)	2015-08-28
IL206081A (en)	2016-11-30
JP5840364B2 (ja)	2016-01-06
BRPI0819714A8 (pt)	2016-05-10
SG10201604258YA (en)	2016-07-28
BRPI0819714A2 (pt)	2015-05-26
JP2014159437A (ja)	2014-09-04
IL206081A0 (en)	2010-11-30
JP2011518110A (ja)	2011-06-23
US8420081B2 (en)	2013-04-16
EP2231175A2 (en)	2010-09-29
WO2009073569A3 (en)	2009-08-27
IL229886B (en)	2018-01-31
IL229886A0 (en)	2014-01-30
WO2009073569A2 (en)	2009-06-11
CA2707483A1 (en)	2009-06-11
CN104645329A (zh)	2015-05-27

Publication	Publication Date	Title
US11167030B2 (en)	2021-11-09	Protein formulations and methods of making same
TW200938221A (en)	2009-09-16	Protein formulations and methods of making same
US20230007847A1 (en)	2023-01-12	Protein formulations and methods of making same
AU2013204044B2 (en)	2017-08-31	Protein formulations and methods of making same